

# Pioglitazone after Ischemic Stroke or Transient Ischemic

New England Journal of Medicine

374, 1321-1331

DOI: [10.1056/nejmoa1506930](https://doi.org/10.1056/nejmoa1506930)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Diabetes Drugs and Cardiovascular Safety. <i>Endocrinology and Metabolism</i> , 2016, 31, 239.	1.3	12
2	Update on pre-diabetes: Focus on diagnostic criteria and cardiovascular risk. <i>World Journal of Diabetes</i> , 2016, 7, 423.	1.3	19
3	Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in) <i>Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50 Pharmacology</i> , 2016, 14, 469-473.	0.8	9
4	Latest clinical research. <i>Independent Nurse</i> , 2016, 2016, 17-17.	0.0	1
5	Cerebrovascular Anatomy, Neuropathology, Clinics of Stroke: Endovascular Treatment, Decompressive Craniectomy. , 0, , .		0
6	Donâ€™t dismiss pioglitazone on basis of uncertain risk. <i>BMJ, The</i> , 2016, 354, i3667.	3.0	0
8	Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the <sc>S</sc>wedish <sc>N</sc>ational <sc>D</sc>iabetes <sc>R</sc>egister. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 990-998.	2.2	44
9	Power of an Adaptive Trial Design for Endovascular Stroke Studies. <i>Stroke</i> , 2016, 47, 2931-2937.	1.0	7
11	Revisiting The Use of Pioglitazone in the Treatment of Type 2 Diabetes. <i>Endocrine Practice</i> , 2016, 22, 1343-1346.	1.1	8
12	Pioglitazone use and risk of bladder cancer: population based cohort study. <i>BMJ, The</i> , 2016, 352, i1541.	3.0	164
13	Pioglitazone and Risk for Bone Fracture: Safety Data from a Randomized Clinical Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, jc.2016-3237.	1.8	62
15	Prediabetes and risk of diabetes and associated complications. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2016, 19, 394-399.	1.3	35
16	Evaluation of exposure to pioglitazone and risk of prostate cancer: a nested case-control study. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000303.	1.2	11
17	Is diabetes still a state of premature cardiovascular death?. <i>Practical Diabetes</i> , 2016, 33, 285-290.	0.1	1
18	Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes. <i>Circulation Research</i> , 2016, 118, 1830-1843.	2.0	51
19	Insulin Resistance Intervention After Stroke Trial of Pioglitazone. <i>Stroke</i> , 2016, 47, 1962-1964.	1.0	1
20	Insulin sensitivity is a Rubikâ€™s Cube. <i>American Journal of Clinical Nutrition</i> , 2016, 103, 1381-1382.	2.2	0
21	EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus. <i>Clinical Therapeutics</i> , 2016, 38, 1288-1298.	1.1	28

#	ARTICLE	IF	CITATIONS
22	What Can We Learn from Interventions That Change Fat Distribution?. Current Obesity Reports, 2016, 5, 271-281.	3.5	6
23	Diabetes and Stroke: Epidemiology, Pathophysiology, Pharmaceuticals and Outcomes. American Journal of the Medical Sciences, 2016, 351, 380-386.	0.4	371
24	Glucose-lowering therapy in type 2 diabetes. Herz, 2016, 41, 208-216.	0.4	3
25	SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. Diabetes Care, 2016, 39, 717-725.	4.3	244
26	A Diagnostic Score for Insulin Resistance in Nondiabetic Patients with Ischemic Stroke or Transient Ischemic Attack. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 1705-1712.	0.7	2
27	The current role of thiazolidinediones in diabetes management. Archives of Toxicology, 2016, 90, 1861-1881.	1.9	54
28	Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk. JAMA Cardiology, 2016, 1, 989.	3.0	77
29	Evidence-based practice use of quick-release bromocriptine across the natural history of type 2 diabetes mellitus. Postgraduate Medicine, 2016, 128, 828-838.	0.9	12
30	Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care, 2016, 39, 1684-1692.	4.3	60
31	Glycemic control and the heart: it matters how you get there. Journal of Diabetes, 2016, 8, 453-454.	0.8	3
32	What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?. Current Diabetes Reports, 2016, 16, 94.	1.7	2
33	Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. New England Journal of Medicine, 2016, 375, 702-704.	13.9	17
34	Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1267-1271.	1.5	8
35	Research roundup: April 2016. NursePrescribing, 2016, 14, 170-171.	0.1	0
36	The Insulin Resistance Intervention after Stroke trial: A perspective on future practice and research. International Journal of Stroke, 2016, 11, 741-743.	2.9	3
37	Treatment of Type 2 Diabetes: From "Guidelines" to "Position Statements" and Back. Diabetes Care, 2016, 39, S146-S153.	4.3	22
38	Insulin Resistance Is a Risk Factor for Silent Lacunar Infarction. Stroke, 2016, 47, 2938-2944.	1.0	34
39	Cardiovascular Outcomes of New Medications for Type 2 Diabetes. Diabetes Technology and Therapeutics, 2016, 18, 749-758.	2.4	7

#	ARTICLE	IF	CITATIONS
40	Authors'™ reply to Gallagher and Winocour. <i>BMJ, The</i> , 2016, 354, i3668.	3.0	0
41	Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease. <i>Diabetes Therapy</i> , 2016, 7, 621-639.	1.2	21
42	The Association between Impaired Glucose Regulation and Prognosis of Chinese Patients with Intracerebral Hemorrhage. <i>Scientific Reports</i> , 2016, 6, 36220.	1.6	4
43	Novel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises Unmet. <i>Current Atherosclerosis Reports</i> , 2016, 18, 79.	2.0	6
44	Implications of the EMPA-REG Trial for Clinical Care and Research. <i>Current Diabetes Reports</i> , 2016, 16, 131.	1.7	7
45	Stroke prevention. <i>Presse Medicale</i> , 2016, 45, e457-e471.	0.8	23
47	Long-term effects of pioglitazone on first attack of ischemic cerebrovascular disease in older people with type 2 diabetes. <i>Medicine (United States)</i> , 2016, 95, e4455.	0.4	9
48	Diabetes medications improve cardiovascular outcomes. <i>Current Opinion in Lipidology</i> , 2016, 27, 633-635.	1.2	0
49	Taking care of volunteers in a stroke trial: a new assisted-management strategy. <i>Stroke and Vascular Neurology</i> , 2016, 1, 108-114.	1.5	1
50	Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 454-462.	2.2	44
51	Pharmacological management of nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1183-1195.	1.5	86
52	Cardiovascular effects of anti-diabetes drugs. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1239-1257.	1.0	14
53	Inflammation and the Silent Sequelae of Stroke. <i>Neurotherapeutics</i> , 2016, 13, 801-810.	2.1	37
54	Clinical Update: Cardiovascular Disease in Diabetes Mellitus. <i>Circulation</i> , 2016, 133, 2459-2502.	1.6	766
57	Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes. <i>Postgraduate Medicine</i> , 2016, 128, 398-408.	0.9	2
58	Insulin Resistance and a Long, Strange Trip. <i>New England Journal of Medicine</i> , 2016, 374, 1378-1379.	13.9	19
60	Antidiabetic agents and cardiovascular outcomes in patients with heart diseases. <i>Current Medical Research and Opinion</i> , 2017, 33, 985-992.	0.9	9
61	Polarization of Microglia/Macrophages in Brain Ischaemia: Relevance for Stroke Therapy. <i>Springer Series in Translational Stroke Research</i> , 2017, , 303-328.	0.1	0

#	ARTICLE	IF	CITATIONS
62	Antihyperglycemic Medications. <i>Physician Assistant Clinics</i> , 2017, 2, 25-38.	0.1	0
63	A New Treatable Risk Factor for Stroke and Atherosclerotic Cardiovascular Disease?. <i>Journal of the American College of Cardiology</i> , 2017, 69, 159-161.	1.2	1
64	Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. <i>BMJ Open</i> , 2017, 7, e013927.	0.8	141
65	Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes. <i>Current Cardiology Reports</i> , 2017, 19, 7.	1.3	42
66	American <sc>D</sc>iabetes <sc>A</sc>ssociation <sc>S</sc>tandards of <sc>M</sc>edical <sc>C</sc>are in <sc>D</sc>iabetes 2017. <i>Journal of Diabetes</i> , 2017, 9, 320-324.	0.8	327
67	Postâ€“Glucose Load Measures of Insulin Resistance and Prognosis of Nondiabetic Patients With Ischemic Stroke. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	29
68	Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 391-402.	5.5	56
69	Liraglutide effects on betaâ€“cell, insulin sensitivity and glucose effectiveness in patients with stable coronary artery disease and newly diagnosed type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 850-857.	2.2	19
70	Nondiabetic Glucometabolic Status and Progression of Aortic Stiffness: The Whitehall II Study. <i>Diabetes Care</i> , 2017, 40, 599-606.	4.3	33
71	Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. <i>Diabetes Care</i> , 2017, 40, 419-430.	4.3	256
72	Insulin Resistance and Prognosis of Nondiabetic Patients With Ischemic Stroke. <i>Stroke</i> , 2017, 48, 887-893.	1.0	63
73	Risk of incident ischemic stroke according to the metabolic health and obesity states in the Vascular-Metabolic CUN cohort. <i>International Journal of Stroke</i> , 2017, 12, 187-191.	2.9	40
74	Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack. <i>Circulation</i> , 2017, 135, 1882-1893.	1.6	53
75	Stroke Risk Factors, Genetics, and Prevention. <i>Circulation Research</i> , 2017, 120, 472-495.	2.0	920
76	Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 535-547.	1.3	17
77	Low dose prednisolone and insulin sensitivity differentially affect arterial stiffness and endothelial function: An open interventional and cross-sectional study. <i>Atherosclerosis</i> , 2017, 258, 34-39.	0.4	12
78	Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis. <i>Annals of Internal Medicine</i> , 2017, 166, 230.	2.0	5
79	Pioglitazone: Good news for diabetic patients with stroke?. <i>European Journal of Internal Medicine</i> , 2017, 39, e24.	1.0	0

#	ARTICLE	IF	CITATIONS
80	Thiazolidinedione use and atrial fibrillation in diabetic patients: a meta-analysis. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 96.	0.7	66
81	After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists?. <i>Diabetes and Metabolism</i> , 2017, 43, 2S3-2S12.	1.4	26
82	Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. <i>Diabetes Care</i> 2016;39:1684-1692. <i>Diabetes Care</i> , 2017, 40, e46-e46.	4.3	2
84	Vitamin D, sub-inflammation and insulin resistance. A window on a potential role for the interaction between bone and glucose metabolism. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 243-258.	2.6	100
85	Family physician-led, team-based, lifestyle intervention in patients with metabolic syndrome: results of a multicentre feasibility project. <i>CMAJ Open</i> , 2017, 5, E229-E236.	1.1	23
86	New Hope For People With Dysglycemia and Cardiovascular Disease Manifestations. <i>Circulation</i> , 2017, 135, 1894-1896.	1.6	6
87	Do triglyceride-lowering drugs decrease risk of cardiovascular disease?. <i>Current Opinion in Lipidology</i> , 2017, 28, 374-379.	1.2	12
88	PPAR $\gamma$ Links BMP2 and TGF $\beta$ 1 Pathways in Vascular Smooth Muscle Cells, Regulating Cell Proliferation and Glucose Metabolism. <i>Cell Metabolism</i> , 2017, 25, 1118-1134.e7.	7.2	163
89	Neurological outcomes of antidiabetic therapy: What the neurologist should know. <i>Clinical Neurology and Neurosurgery</i> , 2017, 158, 60-66.	0.6	3
90	Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis. <i>Diabetes and Metabolism</i> , 2017, 43, 1-8.	1.4	32
91	A Unified Pathophysiological Construct of Diabetes and its Complications. <i>Trends in Endocrinology and Metabolism</i> , 2017, 28, 645-655.	3.1	71
92	Response by Lee et al to Letter Regarding Article, "Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis". <i>Stroke</i> , 2017, 48, e172.	1.0	1
93	Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes. <i>Diabetes and Metabolism</i> , 2017, 43, 299-313.	1.4	28
94	Pharmacologic Treatment of Dyslipidemia in Diabetes: A Case for Therapies in Addition to Statins. <i>Current Cardiology Reports</i> , 2017, 19, 62.	1.3	3
95	Pioglitazone and risk of mortality in patients with type 2 diabetes: results from a European multidatabase cohort study. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000364.	1.2	14
96	Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?. <i>Diabetes Care</i> , 2017, 40, 813-820.	4.3	109
97	Insulin resistance in ischemic stroke. <i>Metabolic Brain Disease</i> , 2017, 32, 1323-1334.	1.4	49
98	Shifting Paradigms in the Medical Management of Type 2 Diabetes: Reflections on Recent Cardiovascular Outcome Trials. <i>Journal of General Internal Medicine</i> , 2017, 32, 1044-1051.	1.3	20

#	ARTICLE	IF	CITATIONS
99	Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. American Journal of Cardiology, 2017, 120, S28-S36.	0.7	45
100	Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. American Journal of Medicine, 2017, 130, S4-S17.	0.6	83
101	Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. American Journal of Medicine, 2017, 130, S18-S29.	0.6	67
102	A review on cardiovascular effects of newer hypoglycaemic medications. Annals of Medicine, 2017, 49, 603-612.	1.5	10
103	Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms. American Journal of Medicine, 2017, 130, S30-S39.	0.6	56
104	The Transcription Factor IRF6 Co-Represses PPAR $\gamma$ -Mediated Cytoprotection in Ischemic Cerebrovascular Endothelial Cells. Scientific Reports, 2017, 7, 2150.	1.6	4
105	Interventions in type 2 diabetes mellitus and cardiovascular mortality—An overview of clinical trials. European Journal of Internal Medicine, 2017, 42, 1-15.	1.0	11
106	Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes. American Journal of Cardiology, 2017, 120, S17-S27.	0.7	66
107	Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies. American Journal of Cardiology, 2017, 120, S4-S16.	0.7	60
108	Neuroanesthesiology Update. Journal of Neurosurgical Anesthesiology, 2017, 29, 97-131.	0.6	1
109	Effects of functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 genetic variants on the pharmacokinetics of insulin sensitizer pioglitazone in Chinese Han individuals. Pharmacogenetics and Genomics, 2017, 27, 125-134.	0.7	3
110	Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?. Current Diabetes Reports, 2017, 17, 21.	1.7	33
111	Insulin provision therapy and mortality in older adults with diabetes mellitus and stable ischemic heart disease: Insights from BARI-2D trial. International Journal of Cardiology, 2017, 241, 35-40.	0.8	14
112	Management of Atherosclerotic Cardiovascular Disease Risk Factors in the Older Adult Patient With Diabetes. Diabetes Care, 2017, 40, 476-484.	4.3	9
113	Is HbA1c<7% a Marker of Poor Performance in Individuals >65 Years Old?. Diabetes Care, 2017, 40, 526-528.	4.3	12
114	Insulin Resistance and Future Cognitive Performance and Cognitive Decline in Elderly Patients with Cardiovascular Disease. Journal of Alzheimer's Disease, 2017, 57, 633-643.	1.2	30
115	Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology. Journal of Cardiology, 2017, 69, 501-507.	0.8	28
116	8. Pharmacologic Approaches to Glycemic Treatment. Diabetes Care, 2017, 40, S64-S74.	4.3	365

#	ARTICLE	IF	CITATIONS
117	Pioglitazone for Secondary Stroke Prevention. <i>Stroke</i> , 2017, 48, 388-393.	1.0	110
118	Pioglitazone improves whole-body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome. <i>Journal of Diabetes Investigation</i> , 2017, 8, 535-541.	1.1	30
119	The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing?. <i>Current Diabetes Reports</i> , 2017, 17, 124.	1.7	17
120	Insulin Therapy Increases Cardiovascular Risk in Type 2 Diabetes. <i>Progress in Cardiovascular Diseases</i> , 2017, 60, 422-434.	1.6	87
121	Pancreatic $\beta$ -Cell Function and Prognosis of Nondiabetic Patients With Ischemic Stroke. <i>Stroke</i> , 2017, 48, 2999-3005.	1.0	13
122	Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction. <i>JAMA Neurology</i> , 2017, 74, 1319.	4.5	21
123	Which Patients With Ischemic Stroke and Insulin Resistance May Benefit From Pioglitazone Hydrochloride?. <i>JAMA Neurology</i> , 2017, 74, 1294.	4.5	0
124	Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 951-964.	5.5	228
125	Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1067, 197-217.	0.8	44
126	Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions. <i>Current Diabetes Reports</i> , 2017, 17, 112.	1.7	22
127	Unbreakable? An analysis of the fragility of randomized trials that support diabetes treatment guidelines. <i>Diabetes Research and Clinical Practice</i> , 2017, 134, 91-105.	1.1	32
128	Selective Inhibition of FOXO1 Activator/Repressor Balance Modulates Hepatic Glucose Handling. <i>Cell</i> , 2017, 171, 824-835.e18.	13.5	160
129	Response by Young et al to Letters Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus". <i>Circulation</i> , 2017, 136, 1567-1568.	1.6	1
130	The shifting paradigm in the treatment of type 2 diabetes mellitus—A cardiologist's perspective. <i>Clinical Cardiology</i> , 2017, 40, 970-973.	0.7	4
131	Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes. <i>Diabetes Care</i> , 2017, 40, 1530-1536.	4.3	45
132	Pharmacological management of type 2 diabetes: what's new in 2017?. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1383-1394.	1.3	19
133	Smoking cessation and outcome after ischemic stroke or TIA. <i>Neurology</i> , 2017, 89, 1723-1729.	1.5	65
134	Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 887-897.	5.5	231



#	ARTICLE	IF	CITATIONS
135	Pioglitazone versus sulfonylureas: cardiovascular outcomes with older diabetes drugs. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 845-847.	5.5	1
136	Targeting cholesterol homeostasis in lung diseases. <i>Scientific Reports</i> , 2017, 7, 10211.	1.6	62
137	Recent Insights into Pharmacologic Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 459-470.	1.3	4
138	Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm. <i>Diabetes Care</i> , 2017, 40, 1121-1127.	4.3	43
139	Is It Time to Change the Type 2 Diabetes Treatment Paradigm? No! Metformin Should Remain the Foundation Therapy for Type 2 Diabetes. <i>Diabetes Care</i> , 2017, 40, 1128-1132.	4.3	32
140	Diabetes-Related Dyslipidemia and Cardiovascular Events. <i>American Journal of the Medical Sciences</i> , 2017, 354, 103-104.	0.4	3
142	Hypothèses mécanistiques pouvant expliquer les effets cardiovasculaires observés avec les inhibiteurs de SGLT2 et les agonistes des récepteurs du GLP-1. <i>Medicine Des Maladies Metaboliques</i> , 2017, 11, 2S37-2S42.	0.1	0
143	Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus. <i>Postgraduate Medicine</i> , 2017, 129, 811-821.	0.9	40
144	Free Fatty Acid Is Associated with Thrombogenicity in Cardioembolic Stroke. <i>Cerebrovascular Diseases</i> , 2017, 44, 160-168.	0.8	13
145	The Role of Diabetes, Obesity, and Metabolic Syndrome in Stroke. <i>Seminars in Neurology</i> , 2017, 37, 267-273.	0.5	16
146	Cardiovascular disease leads to a new algorithm for diabetes treatment. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1126-1133.	0.6	14
147	Can Cardiovascular Epidemiology and Clinical Trials Close the Risk Management Gap Between Diabetes and Prediabetes?. <i>Current Diabetes Reports</i> , 2017, 17, 77.	1.7	7
149	Type 2 Diabetes Mellitus and Impaired Renal Function Are Associated With Brain Alterations and Poststroke Cognitive Decline. <i>Stroke</i> , 2017, 48, 2368-2374.	1.0	43
150	Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack. <i>The Cochrane Library</i> , 2017, 12, CD010693.	1.5	43
151	Global and Regional Effects of Bladder Cancer Risk Associated with Pioglitazone Therapy in Patients with Diabetes. <i>Scientific Reports</i> , 2017, 7, 15804.	1.6	13
152	Treatment options for nonalcoholic steatohepatitis - a safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 903-913.	1.0	23
153	Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure. <i>Current Heart Failure Reports</i> , 2017, 14, 275-283.	1.3	15
154	Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study. <i>BMJ Open</i> , 2017, 7, e015659.	0.8	50

#	ARTICLE	IF	CITATIONS
155	Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus. <i>Annals of Internal Medicine</i> , 2017, 167, 73.	2.0	0
156	Cardiovascular disease prevention strategies for type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1243-1260.	0.9	35
158	Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2017, 7, 1717.	1.6	24
159	Type 2 diabetes, glucose, insulin, BMI, and ischemic stroke subtypes. <i>Neurology</i> , 2017, 89, 454-460.	1.5	84
160	Pioglitazone and cardiovascular risk reduction: time for a second look?. <i>Cardiovascular Endocrinology</i> , 2017, 6, 55-61.	0.8	1
161	The emergence of cardiometabolism. <i>Cardiovascular Endocrinology</i> , 2017, 6, 3-7.	0.8	3
162	Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2017, 8, 33-53.	1.2	14
163	Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. <i>Nature Genetics</i> , 2017, 49, 17-26.	9.4	452
164	Time-to-event methodology improved statistical evaluation in register-based health services research. <i>Journal of Clinical Epidemiology</i> , 2017, 82, 103-111.	2.4	9
165	Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective. <i>Clinical Therapeutics</i> , 2017, 39, 1012-1025.	1.1	15
166	Need for Outcome Scenario Analysis of Clinical Trials in Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2017, 11, 327-334.	1.3	1
167	Therapeutic Targeting of Cellular Stress to Prevent Cardiovascular Disease: A Review of the Evidence. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 83-95.	1.0	11
168	Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 211-223.	1.5	16
169	Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors. <i>Annals of Medicine</i> , 2017, 49, 51-62.	1.5	17
170	SGLT2 Inhibitors—Sweet Success for Diabetic Kidney Disease?. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 7-10.	3.0	19
171	Following the LEADER—why this and other recent trials signal a major paradigm shift in the management of type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 517-519.	1.2	9
172	Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. <i>European Journal of Heart Failure</i> , 2017, 19, 43-53.	2.9	91
173	Pioglitazone in patients with insulin resistance after ischemic stroke or transient ischemic attack: A comment on the IRIS trial. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1-3.	1.2	5

#	ARTICLE	IF	CITATIONS
174	PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. <i>Nature Reviews Endocrinology</i> , 2017, 13, 36-49.	4.3	509
175	Stroke. <i>Lancet, The</i> , 2017, 389, 641-654.	6.3	887
177	Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice. <i>European Respiratory Review</i> , 2017, 26, 170094.	3.0	60
178	Insulin and Other Hypoglycemic Drugs. <i>Side Effects of Drugs Annual</i> , 2017, , 435-446.	0.6	2
179	Cardiovascular Events in Company Employees Occur in Non-obese People without Metabolic Syndrome. <i>Health Evaluation and Promotion</i> , 2017, 44, 492-498.	0.0	0
180	Effects of glucose-lowering agents on ischemic stroke. <i>World Journal of Diabetes</i> , 2017, 8, 270.	1.3	4
181	Reducing sedentary time and fat mass may improve glucose tolerance and insulin sensitivity in adults surviving 6 months after stroke: A phase I pilot study. <i>European Stroke Journal</i> , 2017, 2, 144-153.	2.7	4
182	Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. <i>Cardiovascular Diabetology</i> , 2017, 16, 134.	2.7	89
183	Effects of Lobeglitazone, a New Thiazolidinedione, on Osteoblastogenesis and Bone Mineral Density in Mice. <i>Endocrinology and Metabolism</i> , 2017, 32, 389.	1.3	11
184	Diabetes mellitus and stroke: A clinical update. <i>World Journal of Diabetes</i> , 2017, 8, 235.	1.3	105
185	Recent advances in understanding/managing type 2 diabetes mellitus. <i>F1000Research</i> , 2017, 6, 1922.	0.8	5
186	Antidiabetic Drugs as Antihypertensives: New Data on the Horizon. <i>Current Vascular Pharmacology</i> , 2017, 16, 70-78.	0.8	6
187	Effects of Lobeglitazone, a Novel Thiazolidinedione, on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus over 52 Weeks. <i>Diabetes and Metabolism Journal</i> , 2017, 41, 377.	1.8	21
188	Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus. <i>Journal of Thoracic Disease</i> , 2017, 9, 2124-2134.	0.6	20
189	Basic Concepts in Insulin Resistance and Diabetes Treatment. , 2018, , 19-35.		3
190	2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. <i>Journal of the Chinese Medical Association</i> , 2018, 81, 189-222.	0.6	19
191	Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. <i>Cancer Medicine</i> , 2018, 7, 1070-1080.	1.3	91
192	Effect of pioglitazone on cardiometabolic profiles and safety in patients with type 2 diabetes undergoing percutaneous coronary artery intervention: a prospective, multicenter, randomized trial. <i>Heart and Vessels</i> , 2018, 33, 965-977.	0.5	9

#	ARTICLE	IF	CITATIONS
193	Angptl8 antisense oligonucleotide improves adipose lipid metabolism and prevents diet-induced NAFLD and hepatic insulin resistance in rodents. <i>Diabetologia</i> , 2018, 61, 1435-1446.	2.9	52
194	Antidiabetic drugs for stroke prevention in patients with type-2 diabetes. The neurologist's point of view. <i>Medicina Clínica (English Edition)</i> , 2018, 150, 275-281.	0.1	4
195	PPAR $\beta$ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	198
196	Pioglitazone reduces mortality, prevents depressive-like behavior, and impacts hippocampal neurogenesis in the 6-OHDA model of Parkinson's disease in rats. <i>Experimental Neurology</i> , 2018, 300, 188-200.	2.0	47
197	Glucose-lowering treatment in cardiovascular and peripheral artery disease. <i>Current Opinion in Pharmacology</i> , 2018, 39, 86-98.	1.7	6
198	Rosiglitazone lowers resting and blood pressure response to exercise in men with type 2 diabetes: <sc>A</sc> 1-year randomized study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1740-1750.	2.2	7
199	Prediabetes and Cardiovascular Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 33-50.	1.2	157
200	Keeping Faith With Patients After Stroke or Transient Ischemic Attack. <i>JAMA Neurology</i> , 2018, 75, 404.	4.5	0
201	Diabetes medications and cardiovascular disease: at long last progress. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2018, 25, 87-93.	1.2	11
202	PPAR $\beta$ -activation increases intestinal M1 macrophages and mitigates formation of serrated adenomas in mutant <i>KRAS</i> mice. <i>Oncolmmunology</i> , 2018, 7, e1423168.	2.1	12
203	Complex interplay among adiposity, insulin resistance and bone health. <i>Clinical Obesity</i> , 2018, 8, 131-139.	1.1	26
204	Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies. <i>Diabetologia</i> , 2018, 61, 1503-1516.	2.9	64
205	Diabetes and long-term outcomes of ischaemic stroke: findings from Get With The Guidelines-Stroke. <i>European Heart Journal</i> , 2018, 39, 2376-2386.	1.0	62
206	Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 81-96.	1.2	54
207	Personalizing Glucose-Lowering Therapy in Patients with Type 2 Diabetes and Cardiovascular Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 137-152.	1.2	7
208	Diabetes and ischaemic stroke: a deadly association. <i>European Heart Journal</i> , 2018, 39, 2387-2389.	1.0	10
210	The pharmacological management of metabolic syndrome. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 397-410.	1.3	80
211	Effect of glucose-lowering therapies on heart failure. <i>Nature Reviews Cardiology</i> , 2018, 15, 282-291.	6.1	45

#	ARTICLE	IF	CITATIONS
212	The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus. <i>Heart Failure Reviews</i> , 2018, 23, 445-459.	1.7	9
213	Adipokines in neurovascular diseases. <i>Biomedicine and Pharmacotherapy</i> , 2018, 98, 424-432.	2.5	38
214	Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 558-566.e2.	2.4	154
215	Heart Failure. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 117-135.	1.2	17
216	Antidiabéticos en prevención de ictus en pacientes con diabetes tipo 2. El punto de vista del neurólogo. <i>Medicina Clínica</i> , 2018, 150, 275-281.	0.3	5
218	Necrostatin-1 Improves Long-term Functional Recovery Through Protecting Oligodendrocyte Precursor Cells After Transient Focal Cerebral Ischemia in Mice. <i>Neuroscience</i> , 2018, 371, 229-241.	1.1	52
219	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care™ Expert Forum. <i>Diabetes Care</i> , 2018, 41, 14-31.	4.3	338
220	Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects. <i>Heart Failure Reviews</i> , 2018, 23, 419-437.	1.7	79
221	Have we really demonstrated the cardiovascular safety of anti-hyperglycaemic drugs? Rethinking the concepts of macrovascular and microvascular disease in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1089-1095.	2.2	6
222	Strategies for Achieving Healthy Vascular Aging. <i>Hypertension</i> , 2018, 71, 389-402.	1.3	106
223	Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal</i> , 2018, 39, 2274-2281.	1.0	16
224	The year in cardiology 2017: prevention. <i>European Heart Journal</i> , 2018, 39, 345-353.	1.0	3
225	Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents. <i>Drugs</i> , 2018, 78, 203-214.	4.9	5
226	The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data. <i>Hormones</i> , 2018, 17, 83-95.	0.9	3
227	Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. <i>Kidney International</i> , 2018, 94, 26-39.	2.6	262
228	Precision medicine in the management of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 891-900.	5.5	115
230	Treatment with Oral Drugs. <i>Endocrinology</i> , 2018, , 1-44.	0.1	0
231	Distance from Home to Research Center: A Barrier to In-Person Visits but Not Treatment Adherence in a Stroke Trial. <i>Neuroepidemiology</i> , 2018, 50, 137-143.	1.1	7

#	ARTICLE	IF	CITATIONS
232	Diverse roles of mitochondria in ischemic stroke. <i>Redox Biology</i> , 2018, 16, 263-275.	3.9	280
233	Targeting mitochondrial pyruvate carrier in nonalcoholic steatohepatitis: Growing evidence and future challenges. <i>Hepatology</i> , 2018, 67, 2055-2055.	3.6	0
234	The dark side of browning. <i>Protein and Cell</i> , 2018, 9, 152-163.	4.8	32
235	Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 129-140.	2.2	14
236	Incident ischaemic stroke and Type 2 diabetes: trends in incidence and case fatality in Scotland 2004-2013. <i>Diabetic Medicine</i> , 2018, 35, 99-106.	1.2	19
237	Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke. <i>Circulation</i> , 2018, 137, 455-463.	1.6	45
238	Peroxisome proliferator-activated receptor $\hat{3}$ (PPAR $\hat{3}$ ): A master gatekeeper in CNS injury and repair. <i>Progress in Neurobiology</i> , 2018, 163-164, 27-58.	2.8	156
239	Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 21-27.	0.9	7
240	Antidiabetic drugs and stroke risk. Current evidence. <i>European Journal of Internal Medicine</i> , 2018, 48, 1-5.	1.0	36
241	Energy Balance and Prostate Cancer. <i>Energy Balance and Cancer</i> , 2018, , .	0.2	0
242	Pharmacotherapy of type 2 diabetes: An update. <i>Metabolism: Clinical and Experimental</i> , 2018, 78, 13-42.	1.5	144
243	Practical strategies for improving outcomes in <sc>T2DM</sc>: <sc>T</sc>he potential role of pioglitazone and <sc>DPP4</sc> inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 786-799.	2.2	18
244	Canadian stroke best practice recommendations: Secondary prevention of stroke, sixth edition practice guidelines, update 2017. <i>International Journal of Stroke</i> , 2018, 13, 420-443.	2.9	175
245	Treatment with the PPAR $\hat{3}$ Agonist Pioglitazone in the Early Post-ischemia Phase Inhibits Pro-inflammatory Responses and Promotes Neurogenesis Via the Activation of Innate- and Bone Marrow-Derived Stem Cells in Rats. <i>Translational Stroke Research</i> , 2018, 9, 306-316.	2.3	24
246	An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis. <i>Diabetes Research and Clinical Practice</i> , 2018, 135, 102-110.	1.1	20
247	Pharmaceutical Interventions for Diabetes Prevention in Patients at Risk. <i>American Journal of Cardiovascular Drugs</i> , 2018, 18, 13-24.	1.0	4
248	Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future. <i>Critical Reviews in Toxicology</i> , 2018, 48, 52-108.	1.9	69
249	Artesunate suppresses oxidative and inflammatory processes by activating Nrf2 and ROS-dependent p38 MAPK and protects against cerebral ischemia-reperfusion injury. <i>Molecular Medicine Reports</i> , 2018, 17, 6639-6646.	1.1	39

#	ARTICLE	IF	CITATIONS
250	Pharmacological Intervention for the Prevention of Diabetes Mellitus. Journal of Korean Diabetes, 2018, 19, 140.	0.1	0
251	Tackling Cardiovascular Risk in Type 2 Diabetes: Does Baseline Glucose Control Matter?. EClinicalMedicine, 2018, 4-5, 6-7.	3.2	0
252	Echocardiographic feature of diabetic cardiomyopathy: where are we now?. Cardiovascular Diagnosis and Therapy, 2018, 8, 47-56.	0.7	29
253	SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists. Journal of Clinical Medicine Research, 2018, 10, 615-625.	0.6	12
254	Cardiovascular outcome trials in diabetes: what have we learnt?. Trends in Urology & Men's Health, 2018, 9, 7-12.	0.2	0
255	Cardiovascular Outcomes in Patients With Previous Myocardial Infarction and Mild Diabetes Mellitus Following Treatment With Pioglitazone. EClinicalMedicine, 2018, 4-5, 10-24.	3.2	9
256	Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-of-the-Art Review. Mayo Clinic Proceedings, 2018, 93, 1629-1647.	1.4	31
257	A Precision Medicine Approach to Cerebral Edema and Intracranial Hypertension after Severe Traumatic Brain Injury: Quo Vadis?. Current Neurology and Neuroscience Reports, 2018, 18, 105.	2.0	30
259	Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes. JAMA Network Open, 2018, 1, e186125.	2.8	69
260	The past decade in type 2 diabetes and future challenges. Hormones, 2018, 17, 451-459.	0.9	8
261	Insulin Resistance Index from Oral Glucose Tolerance Test Predicts Ischemic Stroke Outcomes in Non-Diabetic Patients with Different Estimated Glomerular Filtration Rate Strata. Cerebrovascular Diseases, 2018, 46, 140-149.	0.8	2
262	Cardiovascular Safety of Antihyperglycemic Agents: "Do Good or Do No Harm" Drugs, 2018, 78, 1567-1592.	4.9	8
263	Pioglitazone Reduces Dementia Risk in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Analysis. Journal of Clinical Medicine, 2018, 7, 306.	1.0	31
264	Clinical management of type 2 diabetes in south Asia. Lancet Diabetes and Endocrinology, the, 2018, 6, 979-991.	5.5	49
265	Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2018, 61, 2461-2498.	2.9	1,002
266	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet, The, 2018, 392, 2269-2279.	6.3	70
267	Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2018, 41, 2669-2701.	4.3	2,190
268	Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. Expert Opinion on Pharmacotherapy, 2018, 19, 1903-1914.	0.9	18

#	ARTICLE	IF	CITATIONS
269	Pioglitazone Use After Stroke. <i>Circulation</i> , 2018, 138, 1221-1223.	1.6	5
270	Evidence-Based Management of Diabetes in Older Adults. <i>Drugs and Aging</i> , 2018, 35, 1065-1078.	1.3	19
271	Diabetes and Atherosclerosis: Old Players in a New Field, Osteoporosis. <i>Current Vascular Pharmacology</i> , 2018, 16, 524-527.	0.8	11
272	Treatment with Oral Drugs. <i>Endocrinology</i> , 2018, , 527-569.	0.1	0
273	Therapeutic Effects of Targeted PPAR $\delta$ Activation on Inflamed High-Risk Plaques Assessed by Serial Optical Imaging In Vivo. <i>Theranostics</i> , 2018, 8, 45-60.	4.6	23
274	Spotlight on Antidiabetic Agents with Cardiovascular or Renoprotective Benefits. , 2018, 22, 18-034.		2
275	Impact of Bone Fracture on Ischemic Stroke Recovery. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1533.	1.8	11
276	A robust method to estimate regional polygenic correlation under misspecified linkage disequilibrium structure. <i>Genetic Epidemiology</i> , 2018, 42, 636-647.	0.6	3
277	Relation of plasma ceramides to visceral adiposity, insulin resistance and the development of type 2 diabetes mellitus: the Dallas Heart Study. <i>Diabetologia</i> , 2018, 61, 2570-2579.	2.9	67
278	Antihyperglycemic Medications and Impact on Cardiovascular Outcomes: A Review of Current Evidence. <i>Pharmacotherapy</i> , 2018, 38, 739-757.	1.2	3
279	Glucose lowering strategies and cardiovascular disease in type 2 diabetes “teachings from the TOSCA.IT study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2018, 28, 722-726.	1.1	3
280	Accurate diagnosis of diabetes mellitus and new paradigms of classification. <i>Nature Reviews Endocrinology</i> , 2018, 14, 386-387.	4.3	11
281	Relationship Between Glycated Hemoglobin and Stroke Risk: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	58
282	Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2360-2372.	1.2	356
283	Cardiac Autonomic Neuropathy as a Result of Mild Hypercaloric Challenge in Absence of Signs of Diabetes: Modulation by Antidiabetic Drugs. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-19.	1.9	23
284	Evaluation of the HbA1c Reduction Cut Point for a Nonglycemic Effect on Cardiovascular Benefit of Hypoglycemic Agents in Patients with Type 2 Diabetes Based on Endpoint Events. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-7.	0.6	6
286	Cardiovascular and Renal Outcomes of Newer Anti-Diabetic Medications in High-Risk Patients. <i>Current Cardiology Reports</i> , 2018, 20, 65.	1.3	7
287	Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. <i>Circulation</i> , 2018, 138, 1210-1220.	1.6	42



#	ARTICLE	IF	CITATIONS
288	Glucose Lowering Strategies for Cardiac Benefits: Pathophysiological Mechanisms. <i>Physiology</i> , 2018, 33, 197-210.	1.6	3
289	Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration. <i>Molecular Neurodegeneration</i> , 2018, 13, 28.	4.4	57
290	Cardiovascular Disease in Diabetes. , 2018, , 219-237.		0
291	Risk Factors. , 2018, , 17-34.		0
292	Medical Therapies. , 2018, , 357-372.		0
293	Effect of Pioglitazone in Combination with Moderate Dose Statin on Atherosclerotic Inflammation: Randomized Controlled Clinical Trial Using Serial FDG-PET/CT. <i>Korean Circulation Journal</i> , 2018, 48, 591.	0.7	11
294	PPAR Agonists and Metabolic Syndrome: An Established Role?. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1197.	1.8	165
295	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm “ 2018 Executive Summary. <i>Endocrine Practice</i> , 2018, 24, 91-121.	1.1	388
296	Prediabetes and macrovascular disease: Review of the association, influence on outcome and effect of treatment. <i>European Journal of Internal Medicine</i> , 2018, 55, 6-11.	1.0	22
297	SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. <i>Diabetes Care</i> , 2018, 41, 1543-1556.	4.3	137
299	Interventions for improving modifiable risk factor control in the secondary prevention of stroke. <i>The Cochrane Library</i> , 2022, 2022, CD009103.	1.5	84
300	Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study. <i>Cardiovascular Diabetology</i> , 2018, 17, 20.	2.7	37
301	Impact of treatment with pioglitazone on stroke outcomes: A real-world database analysis. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2140-2147.	2.2	18
302	Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR). <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 1035-1039.	1.2	3
303	Goals of Therapy. , 2018, , 227-233.		1
304	Pioglitazone use in patients with diabetes and risk of bladder cancer: a systematic review and meta-analysis. <i>Cancer Management and Research</i> , 2018, Volume 10, 1627-1638.	0.9	24
305	GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A COMPREHENSIVE REVIEW OF HOW TO WEIGH THE OPTIONS, SELECT THE RIGHT PATIENTS, AND MAXIMIZE BENEFITS. <i>Endocrine Practice</i> , 2018, , .	1.1	1
306	Towards more specific treatment for diabetic dyslipidemia. <i>Current Opinion in Lipidology</i> , 2018, 29, 307-312.	1.2	14

#	ARTICLE	IF	CITATIONS
307	Chronic Kidney Disease-Induced Insulin Resistance: Current State of the Field. <i>Current Diabetes Reports</i> , 2018, 18, 44.	1.7	19
308	Serum levels of omentin-1 association with early diagnosis, lesion volume and severity of acute ischemic stroke. <i>Cytokine</i> , 2018, 111, 518-522.	1.4	17
309	Dyslipidemia in Diabetes. , 2019, , 186-198.		3
310	Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 3-14.	2.2	39
311	Calcification biomarkers and vascular dysfunction in obesity and type 2 diabetes: influence of oral hypoglycemic agents. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 317, E658-E666.	1.8	20
312	Treatment of Type 2 Diabetes by Patient Profile in the Clinical Practice of Endocrinology in Spain: Delphi Study Results from the Think Twice Program. <i>Diabetes Therapy</i> , 2019, 10, 1893-1907.	1.2	2
313	Diabetes and stroke. <i>Practical Diabetes</i> , 2019, 36, 126-131.	0.1	1
314	The future of new drugs for diabetes management. <i>Diabetes Research and Clinical Practice</i> , 2019, 155, 107785.	1.1	28
315	Prediabetes: lifestyle, pharmacotherapy or regulation?. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881986302.	1.4	7
316	The PPAR $\alpha$ agonist pioglitazone prevents TGF- $\beta$ 2 induced renal fibrosis by repressing EGR-1 and STAT3. <i>BMC Nephrology</i> , 2019, 20, 245.	0.8	48
317	Prevalence of pre-existing dysglycaemia among inpatients with acute coronary syndrome and associations with outcomes. <i>Diabetes Research and Clinical Practice</i> , 2019, 154, 130-137.	1.1	7
318	From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. <i>JHEP Reports</i> , 2019, 1, 312-328.	2.6	251
319	Homeostasis model assessment of insulin resistance and outcome of ischemic stroke in non-diabetic patients - a prospective observational study. <i>BMC Neurology</i> , 2019, 19, 177.	0.8	16
320	Debate on Insulin vs Non-insulin Use in the Hospital Settingâ€”Is It Time to Revise the Guidelines for the Management of Inpatient Diabetes?. <i>Current Diabetes Reports</i> , 2019, 19, 65.	1.7	43
321	Amelioration of perivascular adipose inflammation reverses vascular dysfunction in a model of nonobese prediabetic metabolic challenge: potential role of antidiabetic drugs. <i>Translational Research</i> , 2019, 214, 121-143.	2.2	27
322	Diabetes and Stroke: The Role of Glucose Regulation. , 2019, , 731-746.		0
323	Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A populationâ€”based cohort study. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2378-2389.	1.1	31
324	Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5055.	1.8	140

#	ARTICLE	IF	CITATIONS
325	Personalized Management of Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2019, 19, 115.	1.7	10
326	Ischemic Stroke Etiology and Secondary Prevention. , 2019, , 119-152.		0
327	A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes. <i>American Journal of Medicine</i> , 2019, 132, S13-S20.	0.6	1
328	Protection against stroke with glucagon-like peptide 1 receptor agonists: a systematic review and meta-analysis. <i>European Journal of Neurology</i> , 2019, 26, 559-565.	1.7	25
329	Upregulation of miR-1306-5p decreases cerebral ischemia/reperfusion injury <i>in vitro</i> by targeting BIK. <i>Bioscience, Biotechnology and Biochemistry</i> , 2019, 83, 2230-2237.	0.6	25
330	Macrophage NCOR1 protects from atherosclerosis by repressing a pro-atherogenic PPAR $\gamma$ signature. <i>European Heart Journal</i> , 2020, 41, 995-1005.	1.0	56
331	Association of Antihyperglycemic Therapy with Risk of Atrial Fibrillation and Stroke in Diabetic Patients. <i>Medicina (Lithuania)</i> , 2019, 55, 592.	0.8	14
332	Diabetes prevention and cardiovascular complications. <i>Diabetologia</i> , 2019, 62, 2161-2162.	2.9	4
333	Inhibition of perivascular mast cell activation is involved in the atheroprotective effect of rosiglitazone in apolipoprotein E-deficient mice. <i>Biochemical and Biophysical Research Communications</i> , 2019, 519, 261-266.	1.0	5
334	Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases. <i>Diabetology and Metabolic Syndrome</i> , 2019, 11, 80.	1.2	38
335	Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. <i>Endocrine Reviews</i> , 2019, 40, 1447-1467.	8.9	210
336	Treating Hepatic Steatosis and Fibrosis by Modulating Mitochondrial Pyruvate Metabolism. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 7, 275-284.	2.3	27
339	Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 133-143.	0.9	155
340	Clinician's Guide to the Updated ABCs of Cardiovascular Disease Prevention: A Review Part 2. <i>American Journal of Medicine</i> , 2019, 132, e599-e609.	0.6	10
341	Neuroprotection in Cerebrovascular Disease. <i>Springer Protocols</i> , 2019, , 175-280.	0.1	0
342	Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3296-3302.	1.8	11
343	Pioglitazone: inexpensive; very effective at reducing HbA 1c ; no evidence of bladder cancer risk; plenty of evidence of cardiovascular benefit. <i>Diabetic Medicine</i> , 2019, 36, 1185-1186.	1.2	6
344	GLUcose COntrol Safety & Efficacy in type 2 Diabetes, a systematic review and NETwork meta-analysis. <i>PLoS ONE</i> , 2019, 14, e0217701.	1.1	14

#	ARTICLE	IF	CITATIONS
345	Effect of pioglitazone in acute ischemic stroke patients with diabetes mellitus: a nested caseâ€“control study. <i>Cardiovascular Diabetology</i> , 2019, 18, 67.	2.7	20
346	Treatment Approaches to Lacunar Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 2055-2078.	0.7	28
347	Understanding Contemporary Use of Thiazolidinediones. <i>Circulation: Heart Failure</i> , 2019, 12, e005855.	1.6	35
348	Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with typeâ€“2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2096-2106.	2.2	6
349	Impaired cross-talk between NO and hyperpolarization in myoendothelial feedback: a novel therapeutic target in early endothelial dysfunction of metabolic disease. <i>Current Opinion in Pharmacology</i> , 2019, 45, 33-41.	1.7	9
350	Effect of thiazolidinedione therapy on the risk of uric acid stones. <i>Kidney International</i> , 2019, 95, 1022-1024.	2.6	4
351	Residual cardiovascular risk among people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 28-38.	2.2	31
352	Pharmacological activation of peroxisome proliferatorâ€“activated receptor $\gamma$ (PPAR $\gamma$ ) protects against hypoxiaâ€“associated fetal growth restriction. <i>FASEB Journal</i> , 2019, 33, 8999-9007.	0.2	23
353	LRP1 Deficiency in Vascular SMC Leads to Pulmonary Arterial Hypertension That Is Reversed by PPAR $\gamma$ Activation. <i>Circulation Research</i> , 2019, 124, 1778-1785.	2.0	46
354	Quantification of Insulin Action in Human Subjects. , 2019, , 3-35.		1
355	Understanding the cardiovascular risk with non-insulin antidiabetic drugs. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 241-251.	1.0	8
357	Dethroning the king?: The future of metformin as first line therapy in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 462-464.	1.2	3
358	Understanding prediabetes: definition, prevalence, burden and treatment options for an emerging disease. <i>Current Medical Research and Opinion</i> , 2019, 35, 1529-1534.	0.9	46
360	Evidence-Based Cardiovascular Risk Management in Diabetes. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 439-448.	1.0	10
361	First cardiovascular event in patients with type 2 diabetes mellitus of a cardiovascular risk management program of a poor Colombian population: a cohort study. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 8.	0.7	4
362	Clinical implications of cardiovascular outcome trials in type 2 diabetes. <i>Herz</i> , 2019, 44, 192-202.	0.4	4
363	Pioglitazone Therapy in Patients With Stroke and Prediabetes. <i>JAMA Neurology</i> , 2019, 76, 526.	4.5	83
364	Potential New Horizons for the Prevention of Cerebrovascular Diseases and Dementia. <i>JAMA Neurology</i> , 2019, 76, 521.	4.5	13

#	ARTICLE	IF	CITATIONS
365	Treatment with MQA, a Derivative of Caffeoylquinic Acid, Provides Neuroprotective Effects against Cerebral Ischemia Through Suppression of the p38 Pathway and Oxidative Stress in Rats. <i>Journal of Molecular Neuroscience</i> , 2019, 67, 604-612.	1.1	11
366	Inhibition of the sodium-glucose co-transporter 2 in the elderly: clinical and mechanistic insights into safety and efficacy. <i>Revista Da Associação Médica Brasileira</i> , 2019, 65, 70-86.	0.3	15
367	High Glucose with Insulin Induces Cell Cycle Progression and Activation of Oncogenic Signaling of Bladder Epithelial Cells Cotreated with Metformin and Pioglitazone. <i>Journal of Diabetes Research</i> , 2019, 2019, 1-10.	1.0	11
368	Long-term effect of pioglitazone vs glimepiride on lipoprotein oxidation in patients with type 2 diabetes: a prospective randomized study. <i>Acta Diabetologica</i> , 2019, 56, 505-513.	1.2	2
369	Nonglycemic Outcomes of Antidiabetic Medications. <i>Clinical Diabetes</i> , 2019, 37, 131-141.	1.2	1
370	The Search for Disease-Modifying Therapies in Pulmonary Hypertension. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019, 24, 334-354.	1.0	22
371	Achievement of Guideline-Recommended Weight Loss Among Patients With Ischemic Stroke and Obesity. <i>Stroke</i> , 2019, 50, 713-717.	1.0	7
372	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary. <i>Endocrine Practice</i> , 2019, 25, 69-101.	1.1	245
373	The VGVAPG Peptide Regulates the Production of Nitric Oxide Synthases and Reactive Oxygen Species in Mouse Astrocyte Cells In Vitro. <i>Neurochemical Research</i> , 2019, 44, 1127-1137.	1.6	15
374	A novel approach for identification of possible GSK-3 <sup>β</sup> inhibitors using computational virtual screening analysis of drugs. <i>International Journal of Computational Biology and Drug Design</i> , 2019, 12, 312.	0.3	0
376	Ponatinib treatment promotes arterial thrombosis and hyperactive platelets. <i>Blood Advances</i> , 2019, 3, 2312-2316.	2.5	16
377	Association between normal triglyceride and insulin resistance in US adults without other risk factors: a cross-sectional study from the US National Health and Nutrition Examination Survey, 2007–2014. <i>BMJ Open</i> , 2019, 9, e028652.	0.8	5
378	Lessons from the Trials for the Desirable Effects of Sodium Glucose Co-Transporter 2 Inhibitors on Diabetic Cardiovascular Events and Renal Dysfunction. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5668.	1.8	13
379	A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes. <i>American Journal of Cardiology</i> , 2019, 124, S12-S19.	0.7	15
380	Pioglitazone May Lower Risk for Recurrent Stroke in Prediabetic Stroke Patients. <i>Neurology Today: an Official Publication of the American Academy of Neurology</i> , 2019, 19, 15-19.	0.0	0
381	Position Paper on the Diagnosis and Treatment of Peripheral Arterial Disease (PAD) in People with Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, S105-S113.	0.6	9
382	Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 73-80.	0.8	56
383	The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5853.	1.8	11

#	ARTICLE	IF	CITATIONS
384	Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack. The Cochrane Library, 2019, CD010693.	1.5	12
385	Thiazolidinediones: the Forgotten Diabetes Medications. Current Diabetes Reports, 2019, 19, 151.	1.7	180
386	Pharmacologic Randomized Clinical Trials in Prevention of Type 2 Diabetes. Current Diabetes Reports, 2019, 19, 154.	1.7	6
387	Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes and Endocrinology, 2019, 7, 313-324.	5.5	566
388	Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. European Heart Journal, 2019, 40, 2907-2919.	1.0	32
389	Detecting pioglitazone use and risk of cardiovascular events using electronic health record data in a large cohort of Chinese patients with type 2 diabetes. Journal of Diabetes, 2019, 11, 684-689.	0.8	9
390	Heart Failure in Type 2 Diabetes Mellitus. Circulation Research, 2019, 124, 121-141.	2.0	411
391	Canagliflozin and Stroke in Type 2 Diabetes Mellitus. Stroke, 2019, 50, 396-404.	1.0	51
392	Prevention of Diabetes Mellitus in Patients With Prediabetes. American Journal of Cardiology, 2019, 123, 507-512.	0.7	31
393	Lipids as risk markers for type 2 diabetes. Journal of Diabetes, 2019, 11, 176-178.	0.8	2
394	MALAT1 Up-Regulator Polydatin Protects Brain Microvascular Integrity and Ameliorates Stroke Through C/EBP $\beta$ /MALAT1/CREB/PGC-1 $\alpha$ /PPAR $\alpha$ Pathway. Cellular and Molecular Neurobiology, 2019, 39, 265-286.	1.7	60
395	Impact of Visceral Adipose Tissue on Clinical Outcomes After Acute Ischemic Stroke. Stroke, 2019, 50, 448-454.	1.0	20
396	Experimental ischaemic stroke induces transient cardiac atrophy and dysfunction. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 54-62.	2.9	30
397	Effects of glucose-lowering agents on surrogate endpoints and hard clinical renal outcomes in patients with type 2 diabetes. Diabetes and Metabolism, 2019, 45, 110-121.	1.4	42
398	Diabetes mellitus inhibits complete recanalization in patients with middle cerebral artery occlusion. Neurological Research, 2019, 41, 60-67.	0.6	1
399	Scoring System to Optimize Pioglitazone Therapy After Stroke Based on Fracture Risk. Stroke, 2019, 50, 95-100.	1.0	9
400	Metabolic syndrome identifies normal weight insulin-resistant stroke patients at risk for recurrent vascular disease. International Journal of Stroke, 2019, 14, 639-645.	2.9	5
401	Prediabetes and Outcome of Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-analysis. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 683-692.	0.7	28

#	ARTICLE	IF	CITATIONS
402	Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine. <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3109.	1.7	70
403	Neuroprotective effects of MHY908, a PPAR $\alpha/\beta$ dual agonist, in a MPTP-induced Parkinson's disease model. <i>Brain Research</i> , 2019, 1704, 47-58.	1.1	25
404	Fracture shortly before stroke in mice leads to hippocampus inflammation and long-lasting memory dysfunction. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 446-455.	2.4	7
405	A performance guide for major risk factors control in patients with atherosclerotic cardiovascular disease in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 674-684.	0.8	10
406	Secondary stroke prevention in patients with type 2 diabetes. Is time for more specific recommendations?. <i>Diabetes Research and Clinical Practice</i> , 2020, 160, 107759.	1.1	0
407	Self-reported painful joint count and assessor-reported tender joint count as instruments to assess pain in hand osteoarthritis. <i>Rheumatology</i> , 2020, 59, 1094-1098.	0.9	4
408	Activation of the Metabolic Master Regulator PPAR $\beta$ : A Potential Pioneering Therapy for Pulmonary Arterial Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2020, 62, 143-156.	1.4	26
409	The role of NLRP3 in traumatic brain injury and its regulation by pioglitazone. <i>Journal of Neurosurgery</i> , 2020, 133, 1083-1091.	0.9	14
410	Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. <i>Endocrine Reviews</i> , 2020, 41, 66-117.	8.9	134
411	Diabetes drugs and stroke risk: Intensive versus conventional glucose-lowering strategies, and implications of recent cardiovascular outcome trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 6-15.	2.2	36
412	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020, 41, 255-323.	1.0	2,811
413	Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study. <i>Journal of Hepatology</i> , 2020, 72, 613-626.	1.8	143
414	Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality. <i>Diabetologia</i> , 2020, 63, 253-260.	2.9	95
415	Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 30-38.	2.2	4
416	Type 2 diabetes mellitus and cardiovascular risk; what the pharmacotherapy can change through the epigenetics. <i>Postgraduate Medicine</i> , 2020, 132, 109-125.	0.9	9
417	Pioglitazone and PPAR $\beta$ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study. <i>Cardiovascular Diabetology</i> , 2020, 19, 2.	2.7	16
418	Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. <i>Diabetes and Metabolism</i> , 2020, 46, 427-441.	1.4	81
419	Pioglitazone Decreased Bone Mineral Density and Bone-Specific Alkaline Phosphatase: A Systematic Review and Meta-analysis. <i>American Journal of Therapeutics</i> , 2020, 27, e701-e704.	0.5	0

#	ARTICLE	IF	CITATIONS
422	The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 106-114.	5.5	77
423	Current aspects of TIA management. <i>Journal of Clinical Neuroscience</i> , 2020, 72, 20-25.	0.8	8
424	PPAR $\beta$ is a gatekeeper for extracellular matrix and vascular cell homeostasis. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 171-179.	1.0	38
425	Trends in pioglitazone use among U.S. adults with type 2 diabetes and suspected nonalcoholic fatty liver disease. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 205-208.	1.9	12
426	Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1670-1681.	1.8	42
427	Microglial V-set and immunoglobulin domain-containing 4 protects against ischemic stroke in mice by suppressing TLR4-regulated inflammatory response. <i>Biochemical and Biophysical Research Communications</i> , 2020, 522, 560-567.	1.0	17
428	Assessing the need for pioglitazone in the treatment of patients with type 2 diabetes: a meta-analysis of its risks and benefits from prospective trials. <i>Scientific Reports</i> , 2020, 10, 15781.	1.6	18
429	Animal models of cerebral ischemia: A review. <i>Biomedicine and Pharmacotherapy</i> , 2020, 131, 110686.	2.5	53
430	The Atherogenic Index of Plasma is Independently Associated with Symptomatic Carotid Artery Stenosis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 105351.	0.7	17
431	A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study. <i>Contemporary Clinical Trials</i> , 2020, 98, 106170.	0.8	53
433	Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. <i>Current Diabetes Reports</i> , 2020, 20, 59.	1.7	39
434	Dysregulated lipid metabolism links NAFLD to cardiovascular disease. <i>Molecular Metabolism</i> , 2020, 42, 101092.	3.0	197
435	Inflammation and adiposity: new frontiers in atrial fibrillation. <i>Europace</i> , 2020, 22, 1609-1618.	0.7	23
436	Bias and Loss to Follow-up in Cardiovascular Randomized Trials: A Systematic Review. <i>Journal of the American Heart Association</i> , 2020, 9, e015361.	1.6	7
437	Is Coronary Artery Disease Inevitable in Type 2 Diabetes? From a Glucentric to a Holistic View on Patient Management. <i>Diabetes Care</i> , 2020, 43, 2001-2009.	4.3	12
438	Atheroprotective effects of 17 $\beta$ -oestradiol are mediated by peroxisome proliferator-activated receptor $\beta$ in human coronary artery smooth muscle cells. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2020, 5, 118-126.	0.5	4
439	Newly Discovered Abnormal Glucose Tolerance in Patients With Acute Myocardial Infarction and Cardiovascular Outcomes: A Meta-analysis. <i>Diabetes Care</i> , 2020, 43, 1958-1966.	4.3	12
440	Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1926-1936.	1.1	7



#	ARTICLE	IF	CITATIONS
441	Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. <i>American Heart Journal</i> , 2020, 229, 61-69.	1.2	137
442	Emerging therapies for right ventricular dysfunction and failure. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 1735-1767.	0.7	13
443	Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2020, 2020, CD013516.	1.5	9
444	Estimate of prevalent ischemic stroke from triglyceride glucose-body mass index in the general population. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 483.	0.7	36
445	Role of peroxisome proliferator-activated receptors in stroke prevention and therapy "The best is yet to come?". <i>Journal of Neuroscience Research</i> , 2020, 98, 2275-2289.	1.3	9
446	New insights into the older hypoglycemic agents in type 2 diabetes therapy. <i>Journal of Diabetes</i> , 2020, 12, 844-847.	0.8	0
447	RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020. <i>International Journal of Diabetes in Developing Countries</i> , 2020, 40, 1-122.	0.3	16
448	Anti-inflammatory and anti-proliferative action of adiponectin mediated by insulin signaling cascade in human vascular smooth muscle cells. <i>Molecular Biology Reports</i> , 2020, 47, 6561-6572.	1.0	6
449	Targeting multiple domains of residual cardiovascular disease risk in patients with diabetes. <i>Current Opinion in Cardiology</i> , 2020, 35, 517-523.	0.8	2
450	Worsening baroreflex sensitivity on progression to type 2 diabetes: localized vs. systemic inflammation and role of antidiabetic therapy. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2020, 319, E835-E851.	1.8	14
451	Metabolic effects of antihyperglycemic agents and mortality: meta-analysis of randomized controlled trials. <i>Scientific Reports</i> , 2020, 10, 12837.	1.6	4
452	Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update "The User's Guide. <i>Canadian Journal of Diabetes</i> , 2020, 44, 592-596.	0.4	12
453	Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6556.	1.8	21
454	Pioglitazone Prevents Hemorrhagic Infarction After Transient Focal Ischemia in Type 2 Diabetes. <i>Neuroscience Research</i> , 2021, 170, 314-321.	1.0	3
455	Comparison of oral glucose tolerance test and HbA1c in detection of disorders of glucose metabolism in patients with acute stroke. <i>Cardiovascular Diabetology</i> , 2020, 19, 204.	2.7	5
456	Clinical Approach to Assessment and Amelioration of Atherosclerotic Vascular Disease in Diabetes. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 582826.	1.1	3
458	Causal associations of insulin resistance with coronary artery disease and ischemic stroke: a Mendelian randomization analysis. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001217.	1.2	31
459	PPAR $\beta$ Deacetylation Confers the Antiatherogenic Effect and Improves Endothelial Function in Diabetes Treatment. <i>Diabetes</i> , 2020, 69, 1793-1803.	0.3	19

#	ARTICLE	IF	CITATIONS
460	Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 418-435.	5.5	105
461	Low Reporting of Cointerventions in Recent Cardiovascular Clinical Trials: A Systematic Review. <i>Journal of the American Heart Association</i> , 2020, 9, e014890.	1.6	5
462	Pioglitazone for primary stroke prevention in Asian patients with type 2 diabetes and cardiovascular risk factors: a retrospective study. <i>Cardiovascular Diabetology</i> , 2020, 19, 94.	2.7	6
463	Triglyceride Glucose Index and Prognosis of Patients With Ischemic Stroke. <i>Frontiers in Neurology</i> , 2020, 11, 456.	1.1	54
464	Noninsulin Therapy for Diabetes. <i>Physician Assistant Clinics</i> , 2020, 5, 153-165.	0.1	0
465	Long-Term Risk of Hip Fracture After Ischemic Stroke. <i>Neurohospitalist, The</i> , 2020, 10, 95-99.	0.3	6
466	Triglyceride glucose index for predicting cardiovascular outcomes after percutaneous coronary intervention in patients with type 2 diabetes mellitus and acute coronary syndrome. <i>Cardiovascular Diabetology</i> , 2020, 19, 31.	2.7	102
467	Paradigm shift in the management of <sc>DM</sc> & <sc>CVD</sc>â€”preventing the next <sc>CV</sc> event. <i>Journal of Diabetes</i> , 2020, 12, 630-632.	0.8	0
468	2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 587-621.	0.6	7
469	Management and prevention of cardiovascular disease for type 2 diabetes: Integrating the diabetes management recommendations of AACE, ADA, EASD, AHA, ACC, and ESC. <i>American Journal of Preventive Cardiology</i> , 2020, 1, 100007.	1.3	2
470	Nonalcoholic Fatty Liver Disease and Implications for Older Adults with Diabetes. <i>Clinics in Geriatric Medicine</i> , 2020, 36, 527-547.	1.0	5
471	Legacy effect of intensive glucose control on major adverse cardiovascular outcome: Systematic review and meta-analyses of trials according to different scenarios. <i>Metabolism: Clinical and Experimental</i> , 2020, 110, 154308.	1.5	41
472	Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitusâ€”Part 1. <i>Cardiology in Review</i> , 2020, 28, 177-189.	0.6	5
473	Escalating cost of oral and injectable antihyperglycemic drugs; are newer medications worth their price? A perspective from India and other developing countries. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 167-169.	1.8	1
475	Response to Letter to the Editor: â€œCardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Careâ€. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e909-e910.	1.8	0
476	Insulin resistance is an independent risk factor for early neurological deterioration in non-diabetic patients with acute ischemic stroke. <i>Neurological Sciences</i> , 2020, 41, 1467-1473.	0.9	6
477	Pioglitazone and bladder cancer: improving research methods. <i>Diabetic Medicine</i> , 2020, 37, 898-899.	1.2	3
478	Relation between HOMA-IR and insulin sensitivity index determined by hyperinsulinemic-euglycemic clamp analysis during treatment with a sodium-glucose cotransporter 2 inhibitor. <i>Endocrine Journal</i> , 2020, 67, 501-507.	0.7	22

#	ARTICLE	IF	CITATIONS
479	Dalceptrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease. <i>Diabetes Care</i> , 2020, 43, 1077-1084.	4.3	21
480	Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1956-1974.	1.2	48
481	Pleural Effusion Due to Use of Pioglitazone: A Case Report. <i>Metabolic Syndrome and Related Disorders</i> , 2020, 18, 168-171.	0.5	5
482	Lack of association between insulin resistance as estimated by homeostasis model assessment and stroke risk: A systematic review and meta-analysis. <i>Medical Hypotheses</i> , 2020, 141, 109700.	0.8	4
483	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2020 Executive Summary. <i>Endocrine Practice</i> , 2020, 26, 107-139.	1.1	410
484	NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. <i>Gut</i> , 2020, 69, 1691-1705.	6.1	369
485	Prediction of Persistent Impaired Glucose Tolerance in Patients with Minor Ischemic Stroke or Transient Ischemic Attack. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104815.	0.7	2
486	Type 2 diabetes mellitus and cardiovascular disease: focus on the effect of antihyperglycemic treatments on cardiovascular outcomes. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 187-199.	0.6	1
487	Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2020, 141, e779-e806.	1.6	157
488	Design and baseline characteristics of the AMPLITUDE cardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 318-323.	2.2	12
489	Prevencción de ictus en pacientes con diabetes mellitus tipo 2 o prediabetes. Recomendaciones del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Espaola de Neurologa. <i>Neurologa</i> , 2021, 36, 305-323.	0.3	5
490	Type 2 diabetes management in people aged over seventy-five years: targets and treatment strategies. <i>Maturitas</i> , 2021, 143, 118-126.	1.0	11
491	Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 24-39.	8.2	174
492	What Are the Current Pharmacological Therapies for Nonalcoholic Fatty Liver Disease?. <i>Journal of Clinical and Experimental Hepatology</i> , 2021, 11, 232-238.	0.4	6
493	COVID-19 and diabetes mellitus: from pathophysiology to clinical management. <i>Nature Reviews Endocrinology</i> , 2021, 17, 11-30.	4.3	653
494	NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. <i>Diabetes and Metabolism</i> , 2021, 47, 101215.	1.4	84
495	Diabetes and stroke: An important complication. <i>Journal of Diabetes</i> , 2021, 13, 184-190.	0.8	16
496	Energy metabolism disorders and potential therapeutic drugs in heart failure. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 1098-1116.	5.7	30

#	ARTICLE	IF	CITATIONS
497	Association of Longitudinal Glycemia with Diffusion Weighted Imaging Lesions in Spontaneous Intracerebral Hemorrhage. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105554.	0.7	3
498	Associations of low-carbohydrate and low-fat intakes with all-cause mortality in subjects with prediabetes with and without insulin resistance. <i>Clinical Nutrition</i> , 2021, 40, 3601-3607.	2.3	8
499	Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH. <i>Molecular Metabolism</i> , 2021, 46, 101153.	3.0	10
500	Thiazolidinediones were associated with higher risk of cardiovascular events in patients with type 2 diabetes and cirrhosis. <i>Liver International</i> , 2021, 41, 110-122.	1.9	8
501	Nuclear receptors in podocyte biology and glomerular disease. <i>Nature Reviews Nephrology</i> , 2021, 17, 185-204.	4.1	36
502	A systematic review of subgroup analyses in randomised clinical trials in cardiovascular disease. <i>Clinical Trials</i> , 2021, 18, 351-360.	0.7	9
504	Metabolic disorders: Sex and gender evidence in dyslipidemia, diabetes, and obesity. , 2021, , 171-205.		0
505	Current Status and Potential Therapeutic Strategies for Using Non-coding RNA to Treat Diabetic Cardiomyopathy. <i>Frontiers in Physiology</i> , 2020, 11, 612722.	1.3	11
506	Diabetes, Lipids, and CV Risk. <i>Current Atherosclerosis Reports</i> , 2021, 23, 8.	2.0	6
507	Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARM $\pm$ ) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?. <i>Current Atherosclerosis Reports</i> , 2021, 23, 3.	2.0	18
508	Insulin resistance is associated with poor functional outcome after acute ischemic stroke in non-diabetic patients. <i>Scientific Reports</i> , 2021, 11, 1229.	1.6	22
509	Evaluation of Browning Agents on the White Adipogenesis of Bone Marrow Mesenchymal Stromal Cells: A Contribution to Fighting Obesity. <i>Cells</i> , 2021, 10, 403.	1.8	9
510	Medical treatment of type 2 diabetes mellitus: Recommendations of the Diabetes, Obesity and Nutrition Group of the Spanish Society of Internal Medicine. <i>Revista Clínica Española</i> , 2021, 221, 101-108.	0.3	4
511	Association between fasting blood glucose and intracranial cerebral artery stenosis: a secondary analysis based on a retrospective cross-sectional study in Korean adults. <i>Acta Diabetologica</i> , 2021, 58, 749-757.	1.2	1
512	Clusterin and Its Role in Insulin Resistance and the Cardiometabolic Syndrome. <i>Frontiers in Immunology</i> , 2021, 12, 612496.	2.2	13
513	Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction Induced Experimentally in Diabetic Rats. <i>Benha Medical Journal</i> , 2021, 38, 147-165.	0.0	0
514	Trans-endothelial trafficking of metabolic substrates and its importance in cardio-metabolic disease. <i>Biochemical Society Transactions</i> , 2021, 49, 507-517.	1.6	2
515	Tratamiento médico de la diabetes mellitus tipo 2: recomendaciones del Grupo de Diabetes, Obesidad y Nutrición de la Sociedad Española de Medicina Interna. <i>Revista Clínica Española</i> , 2021, 221, 101-108.	0.2	4

#	ARTICLE	IF	CITATIONS
516	Diabetes, stroke, and neuroresilience: looking beyond hyperglycemia. <i>Annals of the New York Academy of Sciences</i> , 2021, 1495, 78-98.	1.8	23
517	Comparison Between Pioglitazone/Metformin Combination Therapy and Sitagliptin/Metformin Combination Therapy on the Efficacy in Chinese Type 2 Diabetic Adults Insufficiently Controlled with Metformin: Study Protocol of an Open-Label, Multicenter, Non-Inferiority Parallel-Group Randomized Controlled Trial. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 1243-1252.	1.1	0
518	Association between insulin resistance and post-ischaemic stroke outcome in patients without diabetes: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2021, 11, e044771.	0.8	2
519	Diabetes and Stroke. <i>Journal of Korean Diabetes</i> , 2021, 22, 26-37.	0.1	1
520	Abnormal Glucose Tolerance in Prediabetes Patients with Acute Myocardial Infarction: Implications for Therapy. <i>Journal of Endocrinological Science</i> , 2021, 3, 16-21.	0.1	1
521	A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease. <i>European Cardiology Review</i> , 2021, 16, e11.	0.7	2
522	Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome. <i>Current Atherosclerosis Reports</i> , 2021, 23, 16.	2.0	6
523	Chinese Herbs and Repurposing Old Drugs as Therapeutic Agents in the Regulation of Oxidative Stress and Inflammation in Pulmonary Diseases. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 657-687.	1.6	14
525	The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. <i>Current Diabetes Reports</i> , 2021, 21, 15.	1.7	78
527	Careful use to minimize adverse events of oral antidiabetic medications in the elderly. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 2149-2165.	0.9	18
528	Therapeutic Manipulation of Myocardial Metabolism. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2022-2039.	1.2	40
529	Triglyceride/High-Density Lipoprotein Cholesterol Ratio: A Clue to Metabolic Syndrome, Insulin Resistance, and Severe Atherosclerosis. <i>Lipids</i> , 2021, 56, 405-412.	0.7	19
530	Neurotoxicity of Unconjugated Bilirubin in Neonatal Hypoxic-Ischemic Brain Injury in vitro. <i>Frontiers in Pediatrics</i> , 2021, 9, 659477.	0.9	4
531	Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021, 384, 1248-1260.	13.9	60
532	From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2021, 20, 92.	2.7	28
533	Feasibility trial of metformin XR in people with pre-diabetes and stroke (MIPPS)-randomised open blinded endpoint controlled trial. <i>Journal of Clinical Neuroscience</i> , 2021, 86, 103-109.	0.8	0
534	Nonleisure-Time Physical Activity Guidance Following Minor Ischemic Stroke: A Randomized Clinical Trial. <i>Adapted Physical Activity Quarterly</i> , 2021, 38, 329-347.	0.6	3
535	The Influence of Anti-Diabetic Drugs on Prostate Cancer. <i>Cancers</i> , 2021, 13, 1827.	1.7	12

#	ARTICLE	IF	CITATIONS
536	Stroke prevention in patients with type 2 diabetes mellitus or prediabetes: recommendations of the Spanish Society of Neurology's Stroke Study Group. <i>Neurología (English Edition)</i> , 2021, 36, 305-323.	0.2	2
537	Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?. <i>Journal of Clinical Medicine</i> , 2021, 10, 2040.	1.0	6
538	Komentář k článku: Co má dělat internista u pacienta po ischemické cévně-mozkové příhodě. <i>Vnitřní Lékařství</i> , 2021, 67(1): 7-14 Co má dělat diabetolog u pacienta po iCMP?. <i>Vnitřní Lékařství</i> , 2021, 67, 0.1 e33-e34.		0
539	The risk of carotid plaque instability in patients with metabolic syndrome is higher in women with hypertriglyceridemia. <i>Cardiovascular Diabetology</i> , 2021, 20, 98.	2.7	8
540	Novel therapies with precision mechanisms for type 2 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2021, 17, 364-377.	4.3	70
541	Analysis of the formation of dysglycemia in the substantiation of early pathogenetic therapy of diabetes mellitus. <i>Meditinskij Sovet</i> , 2021, , 33-44.	0.1	0
542	Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug. <i>Cardiovascular Diabetology</i> , 2021, 20, 109.	2.7	54
543	Soluble Epoxide Hydrolase Blockade after Stroke Onset Protects Normal but Not Diabetic Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5419.	1.8	11
544	Treating Diabetes to Prevent Stroke. <i>Stroke</i> , 2021, 52, 1557-1560.	1.0	5
545	Omega-3 fatty acid-rich fish oil supplementation prevents rosiglitazone-induced osteopenia in aging C57BL/6 mice and in vitro studies. <i>Scientific Reports</i> , 2021, 11, 10364.	1.6	10
546	Sodium-Glucose Cotransporter-2 Inhibitors and Protection Against stroke in Patients with type 2 Diabetes and Impaired Renal Function: A Systematic Review and Meta-Analysis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105708.	0.7	8
547	Stroke Prevention: Little-Known and Neglected Aspects. <i>Cerebrovascular Diseases</i> , 2021, 50, 622-635.	0.8	6
548	Cardiovascular impact of new drugs (GLP-1 and gliflozins): the ABCD position statement. <i>British Journal of Diabetes</i> , 2021, 21, 132-148.	0.1	0
549	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021). <i>Eurasian Heart Journal</i> , 2021, , 6-61.	0.2	9
550	The Association Between Second-Line Oral Antihyperglycemic Medication on Types of Dementia in Type 2 Diabetes: A Nationwide Real-World Longitudinal Study. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 1263-1272.	1.2	7
551	Cardiovascular risk management in type 2 diabetes mellitus: A joint position paper of the Italian Cardiology (SIC) and Italian Diabetes (SID) Societies. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 1671-1690.	1.1	5
552	PPAR control of metabolism and cardiovascular functions. <i>Nature Reviews Cardiology</i> , 2021, 18, 809-823.	6.1	299
553	Canadian Stroke Best Practice Recommendations: Secondary Prevention of Stroke Update 2020. <i>Canadian Journal of Neurological Sciences</i> , 2022, 49, 315-337.	0.3	57

#	ARTICLE	IF	CITATIONS
554	Cardiovascular Outcome Trials with Glucose-Lowering Drugs. <i>Current Cardiology Reports</i> , 2021, 23, 75.	1.3	6
555	The brain penetrant PPAR $\delta$ agonist leriglitzazone restores multiple altered pathways in models of X-linked adrenoleukodystrophy. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	24
556	Pioglitazone Inhibits Diabetes-Induced Atrial Mitochondrial Oxidative Stress and Improves Mitochondrial Biogenesis, Dynamics, and Function Through the PPAR- $\delta$ /PGC-1 $\alpha$ Signaling Pathway. <i>Frontiers in Pharmacology</i> , 2021, 12, 658362.	1.6	39
557	A Primary Care Agenda for Brain Health: A Scientific Statement From the American Heart Association. <i>Stroke</i> , 2021, 52, e295-e308.	1.0	37
558	Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients. <i>Transplantation</i> , 2022, 106, 462-478.	0.5	13
559	Pioglitazone use associated with reduced risk of the first attack of ischemic stroke in patients with newly onset type 2 diabetes: a nationwide nested case-control study. <i>Cardiovascular Diabetology</i> , 2021, 20, 152.	2.7	3
560	Telmisartan use and risk of dementia in type 2 diabetes patients with hypertension: A population-based cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003707.	3.9	9
561	Association Between Insulin Resistance and Remote Diffusion-Weighted Imaging Lesions in Primary Intracerebral Hemorrhage. <i>Frontiers in Immunology</i> , 2021, 12, 719462.	2.2	3
562	Downhill hiking improves low-grade inflammation, triglycerides, body weight and glucose tolerance. <i>Scientific Reports</i> , 2021, 11, 14503.	1.6	6
563	Possibilities of application a fixed combination of alogliptin and pioglitazone for type 2 diabetes mellitus treatment. <i>Diabetes Mellitus</i> , 2021, 24, 193-197.	0.5	1
564	Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7605.	1.8	17
565	Post-Treatment with Amorphutin B Evokes PPAR $\delta$ -Mediated Neuroprotection against Hypoxia and Ischemia. <i>Biomedicines</i> , 2021, 9, 854.	1.4	8
566	2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. <i>Stroke</i> , 2021, 52, e364-e467.	1.0	1,123
567	Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP). <i>Science Bulletin</i> , 2021, 66, 1571-1580.	4.3	22
568	Chiglitazar: a novel pan-PPAR agonist. <i>Science Bulletin</i> , 2021, 66, 1497-1498.	4.3	2
569	Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 525-544.	5.5	121
570	Association of Silent Cerebrovascular Disease Identified Using Natural Language Processing and Future Ischemic Stroke. <i>Neurology</i> , 2021, 97, e1313-e1321.	1.5	25
571	Cardioprotective Effects of Pioglitazone in Type 2 Diabetes. <i>Diabetes Spectrum</i> , 2021, 34, 243-247.	0.4	1

#	ARTICLE	IF	CITATIONS
572	Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?. Expert Opinion on Pharmacotherapy, 2021, 22, 1-13.	0.9	2
573	Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study. Hepatology, 2021, 74, 2467-2477.	3.6	10
574	Cardiovascular disease in diabetes, beyond glucose. Cell Metabolism, 2021, 33, 1519-1545.	7.2	87
575	The Aggressive Diabetic Kidney Disease in Youth-Onset Type 2 Diabetes: Pathogenetic Mechanisms and Potential Therapies. Medicina (Lithuania), 2021, 57, 868.	0.8	23
576	Diabetes and COVID-19: The past, the present, and the future. Metabolism: Clinical and Experimental, 2021, 121, 154814.	1.5	60
577	Antihyperglycemic Algorithms for Type 2 Diabetes: Focus on Nonglycemic Outcomes. Diabetes Spectrum, 2021, 34, 248-256.	0.4	1
579	An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy, 2022, 23, 29-42.	0.9	4
580	Advances in Pharmacotherapeutics, Metabolic Surgery, and Technology for Diabetes. Endocrinology and Metabolism Clinics of North America, 2021, 50, 457-474.	1.2	1
581	PPAR $\beta$ and TGF $\beta$ 1 Major Regulators of Metabolism, Inflammation, and Fibrosis in the Lungs and Kidneys. International Journal of Molecular Sciences, 2021, 22, 10431.	1.8	36
582	Evolving Concepts of Type 2 Diabetes Management. Medical Clinics of North America, 2021, 105, 955-966.	1.1	3
583	Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance. BMJ Open, 2021, 11, e046113.	0.8	3
584	Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2021, 161, 1657-1669.	0.6	229
585	Role of diabetes in stroke: Recent advances in pathophysiology and clinical management. Diabetes/Metabolism Research and Reviews, 2022, 38, e3495.	1.7	10
586	Non-alcoholic fatty liver disease: A patient guideline. JHEP Reports, 2021, 3, 100322.	2.6	109
587	Diabetic Cardiomyopathy: Clinical and Metabolic Approach. Current Vascular Pharmacology, 2021, 19, 487-498.	0.8	1
588	Glucose-lowering therapy in patients undergoing percutaneous coronary intervention. EuroIntervention, 2021, 17, e618-e630.	1.4	3
589	Two Unique Mutations in HTRA1-Related Cerebral Small Vessel Disease in North America and Africa and Literature Review. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 106029.	0.7	4
590	Prognosis After Stroke. , 2022, , 207-220.e11.		0



#	ARTICLE	IF	CITATIONS
591	Perspectives of Antidiabetic Drugs in Diabetes With Coronavirus Infections. <i>Frontiers in Pharmacology</i> , 2020, 11, 592439.	1.6	24
592	Constructing a Smartphone-Controlled Semiautomatic Theranostic System for Glucose Homeostasis in Diabetic Mice. <i>Methods in Molecular Biology</i> , 2021, 2312, 141-158.	0.4	0
593	Management of non-alcoholic fatty liver disease. <i>BMJ, The</i> , 2021, 372, m4747.	3.0	99
594	Pathophysiology and Management of Dyslipidemias Associated with Insulin-Resistant States. <i>Contemporary Cardiology</i> , 2021, , 307-322.	0.0	3
595	Interaction of smoking, hyperhomocysteinemia, and metabolic syndrome with carotid atherosclerosis: A cross-sectional study in 972 non-diabetic patients. <i>Nutrition</i> , 2020, 79-80, 110874.	1.1	12
596	ESVM Guideline on peripheral arterial disease. <i>Vasa - European Journal of Vascular Medicine</i> , 2019, 48, 1-79.	0.6	110
597	5 Conservative treatment for PAD â€“ Risk factor management. <i>Vasa - European Journal of Vascular Medicine</i> , 2019, 48, 1-12.	0.6	15
598	Targeting perivascular and epicardial adipose tissue inflammation: therapeutic opportunities for cardiovascular disease. <i>Clinical Science</i> , 2020, 134, 827-851.	1.8	43
600	Peroxisome proliferator-activated receptor gamma blunts endothelin-1-mediated contraction of the uterine artery in a murine model of high-altitude pregnancy. <i>FASEB Journal</i> , 2020, 34, 4283-4292.	0.2	2
602	Oral antidiabetes agents for the management of inpatient hyperglycaemia: so far, yet so close. <i>Diabetic Medicine</i> , 2020, 37, 1418-1426.	1.2	13
603	Reversing the curse on PPAR $\beta$ . <i>Journal of Clinical Investigation</i> , 2018, 128, 2202-2204.	3.9	14
604	Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk. <i>Journal of Clinical Investigation</i> , 2017, 127, 83-93.	3.9	127
605	Distinct but complementary contributions of PPAR isotypes to energy homeostasis. <i>Journal of Clinical Investigation</i> , 2017, 127, 1202-1214.	3.9	270
606	PPAR $\beta$ deacetylation dissociates thiazolidinedione's metabolic benefits from its adverse effects. <i>Journal of Clinical Investigation</i> , 2018, 128, 2600-2612.	3.9	40
607	Stroke Epidemiology and Risk Factor Management. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2017, 23, 15-39.	0.4	278
608	Recent advances in the management of transient ischemic attacks. <i>F1000Research</i> , 2017, 6, 1893.	0.8	8
609	Optimal Cut-Offs of Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) to Identify Dysglycemia and Type 2 Diabetes Mellitus: A 15-Year Prospective Study in Chinese. <i>PLoS ONE</i> , 2016, 11, e0163424.	1.1	68
610	Decrease of cardiovascular risk in patients with type 2 diabetes: review of the common strategies and clinical studies. <i>Diabetes Mellitus</i> , 2018, 21, 193-205.	0.5	8

#	ARTICLE	IF	CITATIONS
611	Prediabetes: Why Should We Care?. Methodist DeBakey Cardiovascular Journal, 2021, 14, 289.	0.5	60
612	Rosiglitazone has a neutral effect on the risk of dementia in type 2 diabetes patients. Aging, 2019, 11, 2724-2734.	1.4	20
613	Pioglitazone and cardiovascular risk in T2DM patients: is it good for all?. Annals of Translational Medicine, 2018, 6, 192-192.	0.7	4
614	Fluoxetine in stroke (FOCUS) trial—reasons to be cheerful about antidepressants in stroke?. Annals of Translational Medicine, 2019, 7, S131-S131.	0.7	3
615	Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications. Current Vascular Pharmacology, 2019, 17, 153-163.	0.8	39
616	Nonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver. Current Hypertension Reviews, 2021, 17, 94-111.	0.5	9
617	Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. Diabetes Care, 2021, 44, 586-594.	4.3	50
618	The durability of oral diabetic medications: Time to A1c baseline and a review of common oral medications used by the primary care provider. , 2018, 2, .		5
619	Type 2 diabetes: Evolving concepts and treatment. Cleveland Clinic Journal of Medicine, 2019, 86, 494-504.	0.6	5
620	SAVOR-TIMI to DECLARE-TIMI: A review on cardiovascular outcome trials of incretin-modulators and gliflozins. Indian Journal of Endocrinology and Metabolism, 2019, 23, 175.	0.2	2
621	RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020. Indian Journal of Endocrinology and Metabolism, 2020, 24, 1.	0.2	85
622	Effects of Thiazolidinedione and New Antidiabetic Agents on Stroke. Journal of Stroke, 2019, 21, 139-150.	1.4	8
623	Virtual screening of novel compounds as potential ER $\alpha$ inhibitors. Bioinformation, 2019, 15, 321-332.	0.2	10
624	Association between Body Fat and Diabetic Peripheral Neuropathy in Middle-Aged Adults with Type 2 Diabetes Mellitus: A Preliminary Report. Journal of Obesity and Metabolic Syndrome, 2019, 28, 112-117.	1.5	24
626	Stroke prevention in diabetes with glucagon-like peptide-1 receptor agonists: A game-changer?. Journal of Diabetes and Its Complications, 2021, 35, 108075.	1.2	0
627	Evidence-based therapeutics for hyperglycemia in hospitalized noncritically ill patients. Current Medical Research and Opinion, 2022, 38, 43-53.	0.9	2
628	Association of Statin Therapy Initiation With Diabetes Progression. JAMA Internal Medicine, 2021, 181, 1562.	2.6	80
629	Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease. JAMA Internal Medicine, 2021, 181, 1575.	2.6	28

#	ARTICLE	IF	CITATIONS
632	Diabetes medications with cardiovascular protection – what now after LEADER®? Could metformin, pioglitazone, empagliflozin and liraglutide complement each other to save lives?. <i>British Journal of Diabetes</i> , 2016, 16, 103.	0.1	6
633	Lessons from Recent Cardiovascular Outcome Trials of Type 2 Diabetes. <i>Journal of Korean Diabetes</i> , 2017, 18, 7.	0.1	0
635	Physiopathological Treatment Approach and Position of Pioglitazone in Type 2 Diabetes. <i>Anadolu KliniÄyi Tıp Bilimleri Dergisi</i> , 0, , .	0.1	1
636	Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes. <i>Contemporary Diabetes</i> , 2018, , 47-69.	0.0	0
637	The Current Role of Glucose Control Medications in Primary and Secondary Prevention for Cardiovascular Disease. <i>MOJ Gerontology &amp; Geriatrics</i> , 2017, 2, .	0.1	0
638	Consequence of Energy Imbalance in Prostate Cancer and Comorbidities. <i>Energy Balance and Cancer</i> , 2018, , 43-70.	0.2	0
639	Fall 57: 73 Jahre, â™, DM Typ 2, Åœbergewicht, Apoplex PrÃvention. , 2018, , 229-232.		0
640	The year in cardiology 2017: prevention. <i>Cardiologia Croatica</i> , 2018, 13, 79-98.	0.0	0
641	Correlation of Glycosylated Hemoglobin And Oral Glucose Tolerance Test Results In Hyperinsulinemic Pre-Impaired Glucose Tolerance State Versus Normoinsulinemic-Normal OGTT. <i>Journal of Medicine University of Santo Tomas</i> , 2018, 2, 155-159.	0.0	0
642	Update on Management of Type 2 Diabetes for Cardiologists. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 14, 273.	0.5	7
643	Mechanisms of cardiovascular protection of non-insulin antidiabetic medications. <i>Diabetes Mellitus</i> , 2018, 21, 376-385.	0.5	0
644	Type 2 Diabetes Mellitus. From the start – combination therapy. <i>Diabetes Mellitus</i> , 2018, 21, 386-394.	0.5	3
645	Approach to the treatment of diabetes in the elderly. <i>Sisli Etfal Hastanesi Tip Bulteni</i> , 2019, 53, 96-102.	0.1	3
646	Strategy and tactics of treatment of type 2 diabetes mellitus. <i>Vnitri Lekarstvi</i> , 2019, 65, 273-278.	0.1	2
647	Pharmacotherapy of Diabetes Focused on Stroke. <i>Journal of the Korean Neurological Association</i> , 2019, 37, 235-250.	0.0	3
649	Periodization of the brain ischemic insult. <i>Klinichna Khirurgiia</i> , 2019, 86, 85-91.	0.0	0
650	Pioglitazone. <i>Vnitri Lekarstvi</i> , 2020, 66, 121-125.	0.1	4
651	Peroxisome proliferator-activated receptor agonists and reversal of vascular degeneration through DNA repair, a step toward drug-induced regenerative medicine. <i>Cardiovascular Endocrinology and Metabolism</i> , 2020, 9, 128-131.	0.5	1

#	ARTICLE	IF	CITATIONS
652	Association Between Hyperhomocysteinemia Combined with Metabolic Syndrome and Higher Prevalence of Stroke in Chinese Adults Who Have Elevated Blood Pressure. <i>Medical Science Monitor</i> , 2022, 27, e934100.	0.5	2
653	Secondary Stroke Prevention and Management for the Neuro-Ophthalmologist. <i>Journal of Neuro-Ophthalmology</i> , 2020, 40, 463-471.	0.4	0
654	Diabetes medications with cardiovascular protection: the likelihood of benefit from combination therapy increases further following new evidence during 2020. <i>British Journal of Diabetes</i> , 2020, 20, 85-88.	0.1	4
655	Pharmacological management of cerebral ischemia in the elderly. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 897-906.	0.9	4
656	L-carnitine supplementation ameliorates insulin resistance in critically ill acute stroke patients: a randomized, double-blinded, placebo-controlled clinical trial. <i>Research in Pharmaceutical Sciences</i> , 2022, 17, 66.	0.6	4
657	Standard Pharmacological Treatment of Diabetes Based on the Guidelines. <i>Stroke Revisited</i> , 2021, , 179-187.	0.2	0
658	Risikofaktoren und Primärprävention. , 2020, , 21-31.		0
660	NAFLD and Cardiovascular and Cardiac Disease: Clinical Implications. , 2020, , 169-197.		0
662	Factors Influencing 1-Year Medication Adherence of Korean Ischemic Stroke Survivors. <i>International Journal of Behavioral Medicine</i> , 2020, 27, 225-234.	0.8	9
663	Medical Management for Secondary Stroke Prevention. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2020, 26, 435-456.	0.4	6
666	Jak postupovat v boji s inzulínovou rezistencí u pacientů s DM 2. typu. <i>Vnitřní Lekarství</i> , 2020, 66, 4-6.	0.1	1
667	The durability of oral diabetic medications: Time to A1c baseline and a review of common oral medications used by the primary care provider. <i>Biological and Applied Environmental Research: an Open Access Peer Reviewed Journal</i> , 2018, 2, .	0.1	11
668	Epigenetics in precision medicine of cardiovascular disease. , 2022, , 347-368.		0
669	Effect of glycemic control on markers of subclinical atherosclerosis in patients with type 2 diabetes mellitus: A review. <i>World Journal of Diabetes</i> , 2021, 12, 1856-1874.	1.3	4
670	MLR-1023 Treatment in Mice and Humans Induces a Thermogenic Program, and Menthol Potentiates the Effect. <i>Pharmaceuticals</i> , 2021, 14, 1196.	1.7	3
671	Non-alcoholic fatty liver disease: Current therapeutic options. <i>Current Opinion in Pharmacology</i> , 2021, 61, 98-105.	1.7	15
672	Evolution in Understanding of Cardiovascular Outcomes in Diabetes. <i>Journal of Diabetes Mellitus</i> , 2021, 11, 378-387.	0.1	0
676	Glycaemic Control in Diabetes. <i>Handbook of Experimental Pharmacology</i> , 2021, , 47-71.	0.9	1

#	ARTICLE	IF	CITATIONS
678	Association of triglyceride-glucose index with clinical outcomes in patients with acute ischemic stroke receiving intravenous thrombolysis. <i>Scientific Reports</i> , 2022, 12, 1596.	1.6	9
679	Transient Ischemic Attack. <i>Advances in Medical Technologies and Clinical Practice Book Series</i> , 2022, , 157-169.	0.3	0
680	Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 367-378.	3.7	92
681	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1-16.	1.1	15
683	Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2022, 145, CIR0000000000001040.	1.6	193
685	The 5 th Annual Heart in Diabetes Conference (part 2). <i>Journal of Diabetes</i> , 2022, 14, 93-96.	0.8	0
686	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108101.	1.2	23
687	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). <i>Digestive and Liver Disease</i> , 2022, 54, 170-182.	0.4	12
688	Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2022, 46, 567-577.	1.8	3
690	Pioglitazone and Risk of Chronic Obstructive Pulmonary Disease in Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study. <i>International Journal of COPD</i> , 2022, Volume 17, 285-295.	0.9	8
691	IMPACT OF ANTIDIABETIC DRUGS ON RISK AND OUTCOME OF COVID-19 INFECTION: A REVIEW. <i>Military Medical Science Letters (Vojenske Zdravotnicke Listy)</i> , 2022, 91, 140-160.	0.2	4
692	BACH2 inhibition reverses $\beta$ 2 cell failure in type 2 diabetes models. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	43
693	Pioglitazone and Prostate Cancer Risk in Taiwanese Male Patients with Type 2 Diabetes: A Retrospective Cohort Study. <i>World Journal of Men's Health</i> , 2023, 41, 119.	1.7	5
694	Triglyceride-glucose index in the development of heart failure and left ventricular dysfunction: analysis of the ARIC study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1531-1541.	0.8	27
696	Interplay of Low-Density Lipoprotein Receptors, LRP6, and Lipoproteins in Pulmonary Hypertension. <i>JACC Basic To Translational Science</i> , 2022, 7, 164-180.	1.9	23
697	The efficacy of pioglitazone for renal protection in diabetic kidney disease. <i>PLoS ONE</i> , 2022, 17, e0264129.	1.1	6
698	Romozosumab and cardiovascular safety—should we learn lessons from pioglitazone?. <i>Osteoporosis International</i> , 2022, , 1.	1.3	0
699	Role of Epicardial Adipose Tissue in Cardiovascular Diseases: A Review. <i>Biology</i> , 2022, 11, 355.	1.3	32

#	ARTICLE	IF	CITATIONS
700	Diabetes and COVID-19; A Bidirectional Interplay. <i>Frontiers in Endocrinology</i> , 2022, 13, 780663.	1.5	38
701	Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1150-1158.	2.2	13
702	Recent Advances in the Treatment of Insulin Resistance Targeting Molecular and Metabolic Pathways: Fighting a Losing Battle?. <i>Medicina (Lithuania)</i> , 2022, 58, 472.	0.8	21
703	Pioglitazone, Bladder Cancer, and the Presumption of Innocence. <i>Current Drug Safety</i> , 2022, 17, 294-318.	0.3	5
704	In Silico Development of Combinatorial Therapeutic Approaches Targeting Key Signaling Pathways in Metabolic Syndrome. <i>Pharmaceutical Research</i> , 2022, , 1.	1.7	0
705	Unwinding Link between Coronavirus and Diabetes Patient. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2022, 22, 1091-1110.	0.6	0
706	New Insights Into Cerebrovascular Pathophysiology and Hypertension. <i>Stroke</i> , 2022, 53, 1054-1064.	1.0	39
707	Thiazolidinedione Use in Individuals With Type 2 Diabetes and Chronic Obstructive Pulmonary Disease. <i>Frontiers in Medicine</i> , 2021, 8, 729518.	1.2	6
708	Management of Hyperglycemia in Older Adults with Type 2 Diabetes. <i>Drugs and Aging</i> , 2022, 39, 39-58.	1.3	5
709	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). <i>Eating and Weight Disorders</i> , 2022, 27, 1603-1619.	1.2	9
710	Association between changes in bodyweight and cardiovascular disease risk factors among obese Japanese patients with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2022, 13, 1560-1566.	1.1	3
711	PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4305.	1.8	28
713	Position Paper on the Diagnosis and Treatment of Peripheral Arterial Disease (PAD) in People with Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2022, 130, S127-S136.	0.6	1
714	Glucose-Lowering and the Risk of Cardiovascular Events With Antidiabetic Therapies: A Systematic Review and Additive-Effects Network Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 876795.	1.1	1
715	Macrovascular Complications. <i>Primary Care - Clinics in Office Practice</i> , 2022, 49, 255-273.	0.7	2
716	European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. <i>European Stroke Journal</i> , 2022, 7, I-XLI.	2.7	51
717	American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings. <i>Endocrine Practice</i> , 2022, 28, 528-562.	1.1	323
718	Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. <i>Cardiovascular Diabetology</i> , 2022, 21, 74.	2.7	82

#	ARTICLE	IF	CITATIONS
719	Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis. <i>BMC Cancer</i> , 2022, 22, 559.	1.1	1
722	Risk of cardiovascular events associated with pathophysiological phenotypes of type 2 diabetes. <i>European Journal of Endocrinology</i> , 2022, 187, 279-291.	1.9	6
723	Expert consensus on personalized initiation of glucose-lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease. <i>Journal of Evidence-Based Medicine</i> , 2022, 15, 168-179.	0.7	3
724	Rethinking the role of pioglitazone in modern diabetology as a cardiorenoprotective agent. <i>Meditsinskiy Sovet</i> , 2022, , 10-21.	0.1	4
725	A synergistic effect of the triglyceride-glucose index and the residual SYNTAX score on the prediction of intermediate-term major adverse cardiac events in patients with type 2 diabetes mellitus undergoing percutaneous coronary intervention. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	9
726	Diabetes: how to manage cardiovascular risk in secondary prevention patients. <i>Drugs in Context</i> , 0, 11, 1-12.	1.0	1
727	Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease. <i>Journal of Diabetes Investigation</i> , 2022, 13, 1472-1488.	1.1	2
728	Measures of Insulin Resistance as a Screening Tool for Dysglycemia in Patients With Coronary Artery Disease: A Report From the EUROASPIRE V Population. <i>Diabetes Care</i> , 2022, 45, 2111-2117.	4.3	4
729	Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?. <i>Endocrinology and Metabolism</i> , 2022, 37, 415-429.	1.3	3
731	Statins and renal disease progression, ophthalmic manifestations, and neurological manifestations in veterans with diabetes: A retrospective cohort study. <i>PLoS ONE</i> , 2022, 17, e0269982.	1.1	3
732	Quality of Care Among Patients with Diabetes and Cerebrovascular Disease. Insights from The Diabetes Collaborative Registry. <i>American Journal of Medicine</i> , 2022, 135, 1336-1341.	0.6	1
733	Central vs site outcome adjudication in the IRIS trial. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2022, 31, 106667.	0.7	0
734	Insulin resistance is associated with an unfavorable outcome among non-diabetic patients with isolated moderate-to-severe traumatic brain injury – A propensity score-matched study. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	1
735	Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial. <i>Cardiovascular Diabetology</i> , 2022, 21, .	2.7	2
736	American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. <i>Endocrine Practice</i> , 2022, 28, 923-1049.	1.1	146
737	Post-stroke cognitive impairment and the risk of stroke recurrence and death in patients with insulin resistance. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2022, 31, 106744.	0.7	3
738	GlycA, hsCRP differentially associated with MI, ischemic stroke: In the Dallas Heart Study and Multi-Ethnic Study of Atherosclerosis. <i>American Journal of Preventive Cardiology</i> , 2022, 12, 100373.	1.3	7
739	Reflections on the state of diabetes research and prospects for treatment. <i>Diabetology International</i> , 2023, 14, 21-31.	0.7	1

#	ARTICLE	IF	CITATIONS
740	Therapie von Begleiterkrankungen: Diabetes mellitus und Dyslipoproteinämie. , 2022, , 211-225.		0
741	Herz und Diabetes. Springer Reference Medizin, 2022, , 1-14.	0.0	0
742	Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2022, 65, 1925-1966.	2.9	273
743	Thirty-six months recurrence after acute ischemic stroke among patients with comorbid type 2 diabetes: A nested case-control study. Frontiers in Aging Neuroscience, 0, 14, .	1.7	2
744	Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2022, 45, 2753-2786.	4.3	435
745	Part Six: Antidiabetic Medication Benefits Beyond Glucose Lowering in Older People. , 2022, 37, 477-487.		0
746	Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2023, 25, 426-434.	2.2	9
747	Differential associations between pre-diabetes, diabetes and stroke occurrence among West Africans. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106805.	0.7	0
748	Use of oral diabetes medications and the risk of incident dementia in US veterans aged ≥60 years with type 2 diabetes. BMJ Open Diabetes Research and Care, 2022, 10, e002894.	1.2	14
750	Triglyceride-glucose index and non-culprit coronary plaque characteristics assessed by optical coherence tomography in patients following acute coronary syndrome: A cross-sectional study. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	4
751	An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes. Medicina (Lithuania), 2022, 58, 1475.	0.8	11
752	Bladder cancer with pioglitazone: A caseâ€“control study. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102637.	1.8	2
753	Pharmacotherapy of type 2 diabetes: An update and future directions. Metabolism: Clinical and Experimental, 2022, 137, 155332.	1.5	35
754	Association of triglyceride-glucose index with ischemic stroke recurrence in nondiabetic patients with small vessel occlusion: a multicenter hospital-based prospective cohort study. Cardiovascular Diabetology, 2022, 21, .	2.7	5
755	Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure. Methodist DeBakey Cardiovascular Journal, 2022, 18, 40-53.	0.5	0
756	Oldies but Goodies: Thiazolidinedione as an Insulin Sensitizer with Cardioprotection. Diabetes and Metabolism Journal, 2022, 46, 827-828.	1.8	3
757	The role of pioglitazone in the fight against insulin resistance, atherosclerosis, cardiovascular disease, and non-alcoholic fatty liver disease. Diabetes Mellitus, 2022, 25, 504-513.	0.5	0
758	Recommendations for Early and Comprehensive Management of Type 2 Diabetes and Its Related Cardio-Renal Complications. Diabetes Therapy, 0, , .	1.2	0



#	ARTICLE	IF	CITATIONS
759	Insulin resistance in ischemic stroke: Mechanisms and therapeutic approaches. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	13
760	Clinical pharmacology of antidiabetic drugs: What can be expected of their use?. <i>Presse Medicale</i> , 2023, 52, 104158.	0.8	6
761	Novel and emerging therapies in pulmonary arterial hypertension. <i>Frontiers in Drug Discovery</i> , 0, 2, .	1.1	1
762	Pioglitazone Has a Null Association with Inflammatory Bowel Disease in Patients with Type 2 Diabetes Mellitus. <i>Pharmaceuticals</i> , 2022, 15, 1538.	1.7	5
763	3. Prevention or Delay of Diabetes and Associated Comorbidities: <i>Standards of Care in Diabetes&#x201c;2023</i>. <i>Diabetes Care</i> , 2023, 46, S41-S48.	4.3	55
764	Caring for Patients With Diabetes in Stroke Neurology. <i>Stroke</i> , 2023, 54, 894-904.	1.0	5
765	Diabetes and Stroke: What Are the Connections?. <i>Journal of Stroke</i> , 2023, 25, 26-38.	1.4	21
766	Recent Pharmacological Options in Type 2 Diabetes and Synergic Mechanism in Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1646.	1.8	18
767	Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	4
768	Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. <i>Journal of Diabetes and Its Complications</i> , 2023, 37, 108389.	1.2	7
769	Impact of Metabolic Activity of Vertebra and Amygdala on Stroke Recurrence: A Prospective Cohort Study. <i>Circulation: Cardiovascular Imaging</i> , 2023, 16, .	1.3	5
770	Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023. , 2023, 5, 100056.		11
771	Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2345.	1.8	12
772	COVID-19: Diabetes Perspective&#x201c;Pathophysiology and Management. <i>Pathogens</i> , 2023, 12, 184.	1.2	7
773	AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2023, 77, 1797-1835.	3.6	358
774	Mediation of Systemic Inflammation on Insulin Resistance and Prognosis of Nondiabetic Patients With Ischemic Stroke. <i>Stroke</i> , 2023, 54, 759-769.	1.0	8
775	Will lobeglitazone rival pioglitazone? A systematic review and critical appraisal. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2023, 17, 102747.	1.8	1
776	Current Treatment Options, Including Diet, Exercise, and Medications. <i>Clinics in Liver Disease</i> , 2023, 27, 397-412.	1.0	0

#	ARTICLE	IF	CITATIONS
777	Xanthine oxidase inhibition and white matter hyperintensity progression following ischaemic stroke and transient ischaemic attack (XILO-FIST): a multicentre, double-blinded, randomised, placebo-controlled trial. <i>EClinicalMedicine</i> , 2023, 57, 101863.	3.2	3
778	Association of COVID-19 with Comorbidities: An Update. <i>ACS Pharmacology and Translational Science</i> , 2023, 6, 334-354.	2.5	13
779	Current management of diabetes patients with COVID-19. <i>Expert Review of Endocrinology and Metabolism</i> , 2023, 18, 199-207.	1.2	1
780	Stroke Prevention and Treatment in People With Type 2 Diabetes: Is There a Role for GLP-1 (Glucagon-Like Peptide-1) Analogues?. <i>Stroke</i> , 2023, 54, 1441-1451.	1.0	2
781	Current management of diabetes patients with COVID-19. <i>Expert Review of Endocrinology and Metabolism</i> , 0, , 1-9.	1.2	0
782	Study on insulin resistance and ischemic cerebrovascular disease: A bibliometric analysis via CiteSpace. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	4
783	Cardiovascular Implications of Metabolic Dysfunction-Associated Fatty Liver Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2023, 52, 459-468.	1.2	4
784	Trends in lipid profile and lipid control among survivors of stroke or myocardial infarction among US adults, 2001â€“2018. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	3
785	Iron, ferroptosis, and ischemic stroke. <i>Journal of Neurochemistry</i> , 2023, 165, 487-520.	2.1	21
786	Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials. <i>Cardiovascular Diabetology</i> , 2023, 22, .	2.7	4
787	Association of theÂ“triglycerideâ€“glucose index with coronary artery disease complexity in patients with acute coronary syndrome. <i>Cardiovascular Diabetology</i> , 2023, 22, .	2.7	13
788	Effects of a Province-wide Triaging System for TIA: The ASPIRE Intervention. <i>Neurology</i> , 0, , 10.1212/WNL.0000000000207201.	1.5	0
789	Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	2
790	Insulin resistance and cardiovascular disease. <i>Journal of International Medical Research</i> , 2023, 51, 030006052311645.	0.4	28
791	Diabetic cardiomyopathy: current state of the problem. Review. <i>Clinical Endocrinology and Endocrine Surgery</i> , 2023, , 58-66.	0.1	0
792	Complex metabolicâ€“endocrine syndromes: associations with cardiovascular disease. , 2023, , 39-81.		1
793	Triglyceride-glucose index, symptomatic intracranial artery stenosis and recurrence risk in minor stroke patients with hypertension. <i>Cardiovascular Diabetology</i> , 2023, 22, .	2.7	4
794	Diabetes as one of the long-term COVID-19 complications: from the potential reason of more diabetic patientsâ€™ susceptibility to COVID-19 to the possible caution of future global diabetes tsunami. <i>Inflammopharmacology</i> , 2023, 31, 1029-1052.	1.9	4

#	ARTICLE	IF	CITATIONS
800	Diabetes and Stroke: The Role of Glucose Regulation. , 2023, , 837-855.		0
802	The PPAR System in Diabetes. Contemporary Diabetes, 2023, , 145-167.	0.0	0
807	Diabetes and Cerebrovascular Disease. Contemporary Cardiology, 2023, , 551-576.	0.0	0
808	Tailoring the Treatment of Type 2 Diabetes Mellitus to the Individual. Contemporary Cardiology, 2023, , 1043-1070.	0.0	0
809	PPARs and Their Emerging Role in Vascular Biology, Inflammation and Atherosclerosis. Contemporary Cardiology, 2023, , 81-97.	0.0	0
810	The Metabolic Syndrome and Vascular Disease. Contemporary Cardiology, 2023, , 375-397.	0.0	0
827	A Systematic Approach to Treating Early Metabolic Disease and Prediabetes. Diabetes Therapy, 2023, 14, 1595-1607.	1.2	0
836	Management of Type 2 Diabetes Mellitus. , 0, , .		0
857	Herz und Diabetes. Springer Reference Medizin, 2023, , 205-218.	0.0	0
865	NAFLD, the hepatic manifestation of the metabolic syndrome. , 2024, , 279-291.		0
866	Role of newer anti-diabetes drugs in prediabetes: A systematic review. , 2024, , 393-406.		0